BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, Miller R, Riaz N, Douillard JY, Andre F, Scarpa A. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol 2019;30:1232-43. [PMID: 31056702 DOI: 10.1093/annonc/mdz116] [Cited by in Crossref: 322] [Cited by in F6Publishing: 351] [Article Influence: 107.3] [Reference Citation Analysis]
Number Citing Articles
1 Russo G, Pepe F, Pisapia P, Palumbo L, Nacchio M, Vigliar E, Pallante P, Parente P, Fassan M, Graziano P, Bellevicine C, Troncone G, Malapelle U, Iaccarino A. Microsatellite instability evaluation of patients with solid tumour: routine practice insight from a large series of Italian referral centre. J Clin Pathol 2023;76:133-6. [PMID: 35545354 DOI: 10.1136/jclinpath-2022-208203] [Reference Citation Analysis]
2 Luchini C, Scarpa A. Microsatellite instability in pancreatic and ampullary carcinomas: histology, molecular pathology, and clinical implications. Hum Pathol 2023;132:176-82. [PMID: 35714836 DOI: 10.1016/j.humpath.2022.06.009] [Reference Citation Analysis]
3 Kullmann F, Strissel PL, Strick R, Stoehr R, Eckstein M, Bertz S, Wullich B, Sikic D, Wach S, Taubert H, Olbert P, Heers H, Lara MF, Macias ML, Matas-Rico E, Lozano MJ, Prieto D, Hierro I, van Doeveren T, Bieche I, Masliah-Planchon J, Beaurepere R, Boormans JL, Allory Y, Herrera-Imbroda B, Hartmann A, Weyerer V. Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort. J Clin Pathol 2023;76:126-32. [PMID: 34583948 DOI: 10.1136/jclinpath-2021-207855] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Ahmad O, Försti A. The complementary roles of genome-wide approaches in identifying genes linked to an inherited risk of colorectal cancer. Hered Cancer Clin Pract 2023;21:1. [PMID: 36707860 DOI: 10.1186/s13053-023-00245-5] [Reference Citation Analysis]
5 Styk J, Pös Z, Pös O, Radvanszky J, Turnova EH, Buglyó G, Klimova D, Budis J, Repiska V, Nagy B, Szemes T. Microsatellite instability assessment is instrumental for Predictive, Preventive and Personalised Medicine: status quo and outlook. EPMA Journal 2023. [DOI: 10.1007/s13167-023-00312-w] [Reference Citation Analysis]
6 Chang X, Wang J, Zhang G, Yang M, Xi Y, Xi C, Chen G, Nie X, Meng B, Quan X. Predicting colorectal cancer microsatellite instability with a self-attention-enabled convolutional neural network. Cell Rep Med 2023;:100914. [PMID: 36720223 DOI: 10.1016/j.xcrm.2022.100914] [Reference Citation Analysis]
7 Ross TJ, Zhang J. The Microbiome-TIME Axis: A Host of Possibilities. Microorganisms 2023;11:288. [DOI: 10.3390/microorganisms11020288] [Reference Citation Analysis]
8 Song XL, Luo HJ, Ren JL, Yin P, Liu Y, Niu J, Hong N. Multisequence magnetic resonance imaging-based radiomics models for the prediction of microsatellite instability in endometrial cancer. Radiol Med 2023. [PMID: 36656410 DOI: 10.1007/s11547-023-01590-0] [Reference Citation Analysis]
9 Wang Q, Xu J, Wang A, Chen Y, Wang T, Chen D, Zhang J, Brismar TB. Systematic review of machine learning-based radiomics approach for predicting microsatellite instability status in colorectal cancer. Radiol Med 2023. [PMID: 36648615 DOI: 10.1007/s11547-023-01593-x] [Reference Citation Analysis]
10 Zhu J, Cao K, Zhao M, Ma K, Jiang X, Bai Y, Ling X, Ma J. Improvement of ACK1-targeted therapy efficacy in lung adenocarcinoma using chloroquine or bafilomycin A1. Mol Med 2023;29:6. [PMID: 36647009 DOI: 10.1186/s10020-023-00602-z] [Reference Citation Analysis]
11 Zhang Y, Liu J, Wu C, Peng J, Wei Y, Cui S. Preoperative Prediction of Microsatellite Instability in Rectal Cancer Using Five Machine Learning Algorithms Based on Multiparametric MRI Radiomics. Diagnostics (Basel) 2023;13. [PMID: 36673079 DOI: 10.3390/diagnostics13020269] [Reference Citation Analysis]
12 Li N, Wan Z, Lu D, Chen R, Ye X. Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review. Front Immunol 2022;13:1088683. [PMID: 36703977 DOI: 10.3389/fimmu.2022.1088683] [Reference Citation Analysis]
13 Amodio V, Lamba S, Chilà R, Cattaneo CM, Mussolin B, Corti G, Rospo G, Berrino E, Tripodo C, Pisati F, Bartolini A, Aquilano MC, Marsoni S, Mauri G, Marchiò C, Abrignani S, Di Nicolantonio F, Germano G, Bardelli A. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance. Cancer Cell 2023;41:196-209.e5. [PMID: 36584674 DOI: 10.1016/j.ccell.2022.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Nasca V, Barretta F, Corti F, Lonardi S, Niger M, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Cremolini C, Ros J, Ambrosini M, Mazzoli G, Intini R, Overman MJ, Miceli R, Pietrantonio F. Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer. J Immunother Cancer 2023;11. [PMID: 36593068 DOI: 10.1136/jitc-2022-005493] [Reference Citation Analysis]
15 Li JJX, Tse GM. Marker assessments in ER-positive breast cancers: old markers, new applications? Histopathology 2023;82:218-31. [PMID: 35945680 DOI: 10.1111/his.14767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Gerasimov AP, Khachatryan WA, Ivanova NE, Kondratev SA, Zabrodskaya YM. Genetic Examination for Emergency Situations: Time, Distance, and Logistics. Lecture Notes in Civil Engineering 2023. [DOI: 10.1007/978-3-030-99877-6_7] [Reference Citation Analysis]
17 Arbitrio M, Cordua A, Uppolo V, D’apolito M, Caracciolo D, Staropoli N, Cuomo O, Fiorillo L, Tassone P, Di Martino M, Tagliaferri P. What is precision medicine in oncology? Liquid Biopsy 2023. [DOI: 10.1016/b978-0-12-822703-9.00002-8] [Reference Citation Analysis]
18 Park YS, Kook M, Kim B, Lee HS, Kang D, Gu M, Shin OR, Choi Y, Lee W, Kim H, Song IH, Kim K, Kim HS, Kang G, Park DY, Jin S, Kim JM, Choi YJ, Chang HK, Ahn S, Chang MS, Han S, Kwak Y, Seo AN, Lee SH, Cho M, The Gastrointestinal Pathology Study Group of the Korean Society of Pathologists. A Standardized Pathology Report for Gastric Cancer: 2nd Edition. J Gastric Cancer 2023;23. [DOI: 10.5230/jgc.2023.23.e7] [Reference Citation Analysis]
19 Rafaniello-Raviele P, Betella I, Rappa A, Vacirca D, Tolva G, Guerrieri-Gonzaga A, Bertario L, Barberis M, Bonanni B, Marabelli M. Microsatellite instability evaluation: which test to use for endometrial cancer? J Clin Pathol 2023;76:29-33. [PMID: 34312297 DOI: 10.1136/jclinpath-2021-207723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Zhao H, Gao J, Bai B, Wang R, Yu J, Lu H, Cheng M, Liang P. Development and external validation of a non-invasive imaging biomarker to estimate the microsatellite instability status of gastric cancer and its prognostic value: the combination of clinical and quantitative CT-imaging features. European Journal of Radiology 2023. [DOI: 10.1016/j.ejrad.2023.110719] [Reference Citation Analysis]
21 Park Y, Nam SK, Seo SH, Park KU, Oh HJ, Park YS, Suh Y, Ahn S, Park DJ, Kim H, Lee HS. Comprehensive Study of Microsatellite Instability Testing and Its Comparison With Immunohistochemistry in Gastric Cancers. J Gastric Cancer 2023;23. [DOI: 10.5230/jgc.2023.23.e5] [Reference Citation Analysis]
22 Wong C, Fu Y, Li M, Mu S, Chu X, Fu J, Lin C, Zhang H. MRI-Based Artificial Intelligence in Rectal Cancer. J Magn Reson Imaging 2023;57:45-56. [PMID: 35993550 DOI: 10.1002/jmri.28381] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Park YS, Kook MC, Kim BH, Lee HS, Kang DW, Gu MJ, Shin OR, Choi Y, Lee W, Kim H, Song IH, Kim KM, Kim HS, Kang G, Park DY, Jin SY, Kim JM, Choi YJ, Chang HK, Ahn S, Chang MS, Han SH, Kwak Y, Seo AN, Cho MY. A standardized pathology report for gastric cancer: 2nd edition. J Pathol Transl Med 2023;57:1-27. [PMID: 36647283 DOI: 10.4132/jptm.2022.12.23] [Reference Citation Analysis]
24 Matsubayashi H, Oishi T, Sasaki K, Abe M, Kiyozumi Y, Higashigawa S, Niiya F, Sato J, Ishiwatari H, Imai K, Hotta K, Kishida Y, Takada K, Ono H, Yamazaki K, Yasui H, Kenmotsu H, Kado N, Kagawa H, Shiomi A, Sugiura T, Bando E, Nishimura S, Hatakeyama K, Serizawa M, Harada R, Sugino T. Discordance of microsatellite instability and mismatch repair immunochemistry occurs depending on the cancer type. Hum Pathol 2022:S0046-8177(22)00293-3. [PMID: 36596344 DOI: 10.1016/j.humpath.2022.12.016] [Reference Citation Analysis]
25 Basudan AM. The Role of Immune Checkpoint Inhibitors in Cancer Therapy. Clin Pract 2022;13:22-40. [PMID: 36648843 DOI: 10.3390/clinpract13010003] [Reference Citation Analysis]
26 Bai Y, Cao K, Zhang P, Ma J, Zhu J. Prognostic and Immunological Implications of FAM72A in Pan-Cancer and Functional Validations. Int J Mol Sci 2022;24. [PMID: 36613817 DOI: 10.3390/ijms24010375] [Reference Citation Analysis]
27 Élez E, Mulet-Margalef N, Sanso M, Ruiz-Pace F, Mancuso FM, Comas R, Ros J, Argilés G, Martini G, Sanz-Garcia E, Baraibar I, Salvà F, Noguerido A, Cuadra-Urteaga JL, Fasani R, Garcia A, Jimenez J, Aguilar S, Landolfi S, Hernández-Losa J, Braña I, Nuciforo P, Dienstmann R, Tabernero J, Salazar R, Vivancos A. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy. Int J Mol Sci 2022;24. [PMID: 36613564 DOI: 10.3390/ijms24010118] [Reference Citation Analysis]
28 Krämer A, Bochtler T, Pauli C, Baciarello G, Delorme S, Hemminki K, Mileshkin L, Moch H, Oien K, Olivier T, Patrikidou A, Wasan H, Zarkavelis G, Pentheroudakis G, Fizazi K; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022:S0923-7534(22)04769-X. [PMID: 36563965 DOI: 10.1016/j.annonc.2022.11.013] [Reference Citation Analysis]
29 Dazio G, Epistolio S, Frattini M, Saletti P. Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. J Clin Med 2022;11. [PMID: 36556139 DOI: 10.3390/jcm11247523] [Reference Citation Analysis]
30 Kao CH, Liu CT, Lin H, Huang YC, Lan J, Ou YC, Fu HC, Wu CH. Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma. Front Immunol 2022;13:1079253. [PMID: 36591227 DOI: 10.3389/fimmu.2022.1079253] [Reference Citation Analysis]
31 Voutilainen S, Heikkilä P, Bartkova J, Nevanlinna H, Blomqvist C, Bartek J, Mattson J. Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases. BMC Cancer 2022;22:1298. [PMID: 36503417 DOI: 10.1186/s12885-022-10408-7] [Reference Citation Analysis]
32 Sun Q, Du J, Dong J, Pan S, Jin H, Han X, Zhang J. Systematic Investigation of the Multifaceted Role of SOX11 in Cancer. Cancers (Basel) 2022;14. [PMID: 36551589 DOI: 10.3390/cancers14246103] [Reference Citation Analysis]
33 Garzón-Hernández C, Ramírez-Merino N, Soberon MCM. Molecular Targeted Therapy in Oncology Focusing on DNA Repair Mechanisms. Arch Med Res 2022;53:807-17. [PMID: 36460545 DOI: 10.1016/j.arcmed.2022.11.007] [Reference Citation Analysis]
34 Qiu Q, Li J, Chen Q, Zhao X, Zhou R, Zhang W, Gong Z, Zhang D, Wang M. Assessment of PD-L1 mRNA expression in gastrointestinal tumors and the response to immunotherapy. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.926746] [Reference Citation Analysis]
35 Alam MR, Kim YH, Alhazmi A, Haque S, Kang YN, Jung HR, Sohn MY, Kim DK. Analysis of microsatellite instability in Korean patients with pancreatic cancer. Minerva Med 2022;113:959-66. [PMID: 34913638 DOI: 10.23736/S0026-4806.21.07669-2] [Reference Citation Analysis]
36 Yang Y, Zhang G, Hu C, Luo W, Jiang H, Liu S, Yang H. The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk. BMC Urol 2022;22:196. [PMID: 36451132 DOI: 10.1186/s12894-022-01141-1] [Reference Citation Analysis]
37 Wang C, Wang Z, Zhao Y, Jia R. Tumor mutation burden-related long non-coding RNAs is predictor for prognosis and immune response in pancreatic cancer. BMC Gastroenterol 2022;22:495. [PMID: 36451085 DOI: 10.1186/s12876-022-02535-z] [Reference Citation Analysis]
38 Kang YJ, O'Haire S, Franchini F, IJzerman M, Zalcberg J, Macrae F, Canfell K, Steinberg J. A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours. Sci Rep 2022;12:20495. [PMID: 36443366 DOI: 10.1038/s41598-022-23319-1] [Reference Citation Analysis]
39 Laktionov KK, Artamonova EV, Borisova TN, Breder VV, Bychkov IM, Vladimirova LI, Volkov NM, Ergnian SM, Zhabina AS, Kononets PV, Kuzminov AE, Levchenko EV, Malikhova OA, Marinov DT, Miller SV, Moiseenko FV, Mochal’nikova VV, Novikov SN, Pikin OV, Reutova EV, Rodionov EO, Sakaeva DD, Sarantseva KA, Semenova AI, Smolin AV, Sotnikov VM, Tuzikov SA, Turkin IN, Tyurin IE, Chkhikvadze VD, Kolbanov KI, Chernykh MV, Chernichenko AV, Fedenko AA, Filonenko EV, Nevol’skikh AA, Ivanov SA, Khailova ZV, Gevorkian TG, Butenko AV, Gil’mutdinova IR, Gridneva IV, Eremushkin MA, Zernova MA, Kasparov BS, Kovlen DV, Kondrat’eva KO, Konchugova TV, Korotkova SB, Krutov AA, Obukhova OA, Ponomarenko GN, Semiglazova TI, Stepanova AM, Khulamkhanova MM. Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. J Mod Onco 2022;24:269-304. [DOI: 10.26442/18151434.2022.3.201848] [Reference Citation Analysis]
40 Sun Y, Li H, Ma Z, Wang J, Yang H, Zhang X, Liu B. Identification of immune subtypes and their prognosis and molecular implications in colorectal cancer. PLoS One 2022;17:e0278114. [PMID: 36417424 DOI: 10.1371/journal.pone.0278114] [Reference Citation Analysis]
41 Hou W, Yi C, Zhu H. Predictive biomarkers of colon cancer immunotherapy: Present and future. Front Immunol 2022;13:1032314. [PMID: 36483562 DOI: 10.3389/fimmu.2022.1032314] [Reference Citation Analysis]
42 Marques AC, Ferraro-peyret C, Michaud F, Song L, Smith E, Fabre G, Willig A, Wong MML, Xing X, Chong C, Brayer M, Fenouil T, Hervieu V, Bancel B, Devouassoux M, Balme B, Meyronet D, Menu P, Lopez J, Xu Z. Improved NGS-based detection of microsatellite instability using tumor-only data. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.969238] [Reference Citation Analysis]
43 Li W, Yang G, Dong H, Zhu J, Liu T. A prognostic signature based on cuprotosis-related long non-coding RNAs predicts the prognosis and sensitivity to chemotherapy in patients with colorectal cancer. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1055785] [Reference Citation Analysis]
44 Marín-Jiménez JA, García-Mulero S, Matías-Guiu X, Piulats JM. Facts and Hopes in Immunotherapy of Endometrial Cancer. Clin Cancer Res 2022;28:4849-60. [PMID: 35789264 DOI: 10.1158/1078-0432.CCR-21-1564] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
45 Chen J, Song YW, Liang GZ, Zhang ZJ, Wen XF, Li RB, Chen YL, Pan WD, He XW, Hu T, Xian ZY. A Novel m7G-Related Gene Signature Predicts the Prognosis of Colon Cancer. Cancers (Basel) 2022;14. [PMID: 36428620 DOI: 10.3390/cancers14225527] [Reference Citation Analysis]
46 Olivier T, Prasad V. Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment. BMC Med 2022;20:392. [DOI: 10.1186/s12916-022-02589-6] [Reference Citation Analysis]
47 Martinelli E, Cremolini C, Mazard T, Vidal J, Virchow I, Tougeron D, Cuyle PJ, Chibaudel B, Kim S, Ghanem I, Asselain B, Castagné C, Zkik A, Khan S, Arnold D. Real-world first-line treatment of patients with BRAF(V600E)-mutant metastatic colorectal cancer: the CAPSTAN CRC study. ESMO Open 2022;7:100603. [PMID: 36368253 DOI: 10.1016/j.esmoop.2022.100603] [Reference Citation Analysis]
48 Li Z, Pu Z, Yang Z, Zhu Y, Deng Y, Li N, Peng F. Pan-cancer analysis of trophinin-associated protein with potential implications in clinical significance, prognosis, and tumor microenvironment in human cancers. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.971618] [Reference Citation Analysis]
49 Vidula N, Lipman A, Kato S, Weipert C, Hesler K, Azzi G, Elkhanany A, Juric D, Rodriguez E, Faulkner C, Makhlouf P, Price K, O’shaughnessy J, Bardia A. Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer. npj Breast Cancer 2022;8:117. [DOI: 10.1038/s41523-022-00490-2] [Reference Citation Analysis]
50 Kulkarni A, Wafik M. Genomics makes prostate cancer personal. Trends Urol & Men's Health 2022;13:7-13. [DOI: 10.1002/tre.883] [Reference Citation Analysis]
51 Bai H, Han H, Wang F, Shi H. Chemotherapy combined with immunotherapy in primary female urethral squamous cell carcinoma: a case report. J Int Med Res 2022;50:3000605221132418. [PMID: 36281031 DOI: 10.1177/03000605221132418] [Reference Citation Analysis]
52 Dong S, Hou D, Peng Y, Chen X, Li H, Wang H. Pan-Cancer Analysis of the Prognostic and Immunotherapeutic Value of MITD1. Cells 2022;11:3308. [PMID: 36291174 DOI: 10.3390/cells11203308] [Reference Citation Analysis]
53 Traub B, Scheufele F, Viswanathan SR, Meyerson M, Tuveson DA. Molecular Biology, Genetics, and Translational Models of Human Cancer. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm003.pub2] [Reference Citation Analysis]
54 Liu T, Qi J, Wu H, Wang L, Zhu L, Qin C, Zhang J, Zhu Q. Phosphogluconate dehydrogenase is a predictive biomarker for immunotherapy in hepatocellular carcinoma. Front Oncol 2022;12:993503. [DOI: 10.3389/fonc.2022.993503] [Reference Citation Analysis]
55 Ben X, Tian D, Zhuang W, Chen R, Wang S, Zhou Z, Deng C, Shi R, Liu S, Zhang D, Tang J, Xie L, Zhou H, Zhang Z, Li M, Zhang X, Qiao G. Accuracy of next-generation sequencing for molecular profiling of small specimen of lung cancer: a prospective pilot study of side-by-side comparison. Diagn Pathol 2022;17:78. [PMID: 36224661 DOI: 10.1186/s13000-022-01255-y] [Reference Citation Analysis]
56 Borelli B, Antoniotti C, Carullo M, Germani MM, Conca V, Masi G. Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability. Cancers 2022;14:4974. [DOI: 10.3390/cancers14204974] [Reference Citation Analysis]
57 Chen Y, Huang A, Yang Q, Yu J, Li G. Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer. Front Immunol 2022;13:987345. [DOI: 10.3389/fimmu.2022.987345] [Reference Citation Analysis]
58 Puccini A, Seeber A, Berger MD. Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective. Cancers 2022;14:4828. [DOI: 10.3390/cancers14194828] [Reference Citation Analysis]
59 Zhang G, Fu L, Wang Y, Liu B, Ma S, Ma H, Zhang H, Zhang F, Yang K, Cai H. Integrative pan-cancer analysis indicates the prognostic importance of long noncoding RNA SNHG17 in human cancers. Pathol Res Pract 2022;238:154140. [PMID: 36167008 DOI: 10.1016/j.prp.2022.154140] [Reference Citation Analysis]
60 Stintzing S, Jelas I. Prognostische und prädiktive Biomarker beim kolorektalen Karzinom. TD 2022;20:184-190. [DOI: 10.47184/td.2022.03.03] [Reference Citation Analysis]
61 Rumyantsev AA. Efficient sequence of therapy for advanced and metastatic endometrial cancer. Opuholi ženskoj reproduktivnoj sistemy 2022;18:119-126. [DOI: 10.17650/1994-4098-2022-18-2-119-126] [Reference Citation Analysis]
62 Zeng Q, Zhu Y, Li L, Feng Z, Shu X, Wu A, Luo L, Cao Y, Tu Y, Xiong J, Zhou F, Li Z. CT-based radiomic nomogram for preoperative prediction of DNA mismatch repair deficiency in gastric cancer. Front Oncol 2022;12:883109. [DOI: 10.3389/fonc.2022.883109] [Reference Citation Analysis]
63 Parmar K, Subramanyam S, Attwood K, Appiah D, Fountzilas C, Mukherjee S. Anti PD-1/Anti PDL-1 Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized Controlled Trials. Pharmaceutics 2022;14:1953. [DOI: 10.3390/pharmaceutics14091953] [Reference Citation Analysis]
64 Taieb J, Svrcek M, Cohen R, Basile D, Tougeron D, Phelip JM. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment. Eur J Cancer 2022;175:136-57. [PMID: 36115290 DOI: 10.1016/j.ejca.2022.07.020] [Reference Citation Analysis]
65 Yang Z, Wu G, Zhang X, Gao J, Meng C, Liu Y, Wei Q, Sun L, Wei P, Bai Z, Yao H, Zhang Z. Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer. Front Immunol 2022;13:1001444. [DOI: 10.3389/fimmu.2022.1001444] [Reference Citation Analysis]
66 Han X, Ye J, Huang R, Li Y, Liu J, Meng T, Song D. Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect. Front Immunol 2022;13:900273. [DOI: 10.3389/fimmu.2022.900273] [Reference Citation Analysis]
67 Chen B, Zhou X, Yang L, Zhou H, Meng M, Wu H, Liu Z, Zhang L, Li C. Glioma stem cell signature predicts the prognosis and the response to tumor treating fields treatment. CNS Neurosci Ther 2022. [PMID: 36070228 DOI: 10.1111/cns.13956] [Reference Citation Analysis]
68 Abiko K, Hamanishi J, Matsumura N, Mandai M. Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after "IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer". Br J Cancer 2022. [PMID: 36068276 DOI: 10.1038/s41416-022-01960-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Aminder S, Saveena J, Ankita S, Harpreet K, Kunal J, Vikram N, Sumit G, Bhavna G, Ramneek K. Histopathological Predictors of Microsatellite Instability in Colorectal Cancer—a Tertiary Care Center Experience. Indian J Surg Oncol 2022. [DOI: 10.1007/s13193-022-01633-4] [Reference Citation Analysis]
70 Schöniger S, Rüschoff J. Mismatch Repair Deficiency and Microsatellite Instability. Encyclopedia 2022;2:1559-1576. [DOI: 10.3390/encyclopedia2030106] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 Lai J, Yang S, Chu S, Xu T, Huang J. Determination of a prediction model for therapeutic response and prognosis based on chemokine signaling-related genes in stage I–III lung squamous cell carcinoma. Front Genet 2022;13:921837. [DOI: 10.3389/fgene.2022.921837] [Reference Citation Analysis]
72 Hestetun KE, Rosenlund NB, Stanisavljević L, Dahl O, Myklebust MP. Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer. Front Oncol 2022;12:853545. [DOI: 10.3389/fonc.2022.853545] [Reference Citation Analysis]
73 Ji H, Zhang Q, Wang XX, Li J, Wang X, Pan W, Zhang Z, Ma B, Zhang HM. Identification of stromal microenvironment characteristics and key molecular mining in pancreatic cancer. Discov Oncol 2022;13:83. [PMID: 36006549 DOI: 10.1007/s12672-022-00532-y] [Reference Citation Analysis]
74 Sun Z, Zhao Y, Wei Y, Ding X, Tan C, Wang C. Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma. Front Immunol 2022;13:939523. [DOI: 10.3389/fimmu.2022.939523] [Reference Citation Analysis]
75 Gambini D, Ferrero S, Kuhn E. Lynch Syndrome: From Carcinogenesis to Prevention Interventions. Cancers 2022;14:4102. [DOI: 10.3390/cancers14174102] [Reference Citation Analysis]
76 Kwon MJ. Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer. Arch Pharm Res 2022. [PMID: 35982262 DOI: 10.1007/s12272-022-01402-5] [Reference Citation Analysis]
77 Kristeleit R, Mathews C, Redondo A, Boklage S, Hanlon J, Im E, Brown J. Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab. Int J Gynecol Cancer 2022:ijgc-2022-003492. [PMID: 35973737 DOI: 10.1136/ijgc-2022-003492] [Reference Citation Analysis]
78 Ding M, Li Q, Tan X, Zhang L, Tan J, Zheng L. Comprehensive pan-cancer analysis reveals the prognostic value and immunological role of SPIB. Aging. [DOI: 10.18632/aging.204225] [Reference Citation Analysis]
79 Hamada K, Tsunoda T, Yoshimura K. Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors. Life (Basel) 2022;12:1229. [PMID: 36013407 DOI: 10.3390/life12081229] [Reference Citation Analysis]
80 Garg V, Jayaraj AS, Kumar L. Novel approaches for treatment of endometrial carcinoma. Curr Probl Cancer 2022;46:100895. [PMID: 35986972 DOI: 10.1016/j.currproblcancer.2022.100895] [Reference Citation Analysis]
81 Jiao Z, Feng X, Cui Y, Wang L, Gan J, Zhao Y, Meng Q. Expression characteristic, immune signature, and prognosis value of EFNA family identified by multi-omics integrative analysis in pan-cancer. BMC Cancer 2022;22:871. [PMID: 35945523 DOI: 10.1186/s12885-022-09951-0] [Reference Citation Analysis]
82 Prieto-potin I, Idrovo F, Suárez-gauthier A, Díaz-blázquez M, Astilleros-blanco de Córdova L, Chamizo C, Zazo S, Carvajal N, López-sánchez A, Pérez-buira S, Aúz-alexandre CL, Manso R, Plaza-sánchez J, de Lucas-lópez V, Pérez-gonzález N, Martín-valle S, Cristóbal I, Casado V, García-foncillas J, Rojo F. Comprehensive Approach to Genomic and Immune Profiling: Insights of a Real-World Experience in Gynecological Tumors. Diagnostics 2022;12:1903. [DOI: 10.3390/diagnostics12081903] [Reference Citation Analysis]
83 Jiang Y, Wang X, Li L, He J, Jin Q, Long D, Liu C, Zhou W, Liu K. A systematic analysis of C5ORF46 in gastrointestinal tumors as a potential prognostic and immunological biomarker. Front Genet 2022;13:926943. [DOI: 10.3389/fgene.2022.926943] [Reference Citation Analysis]
84 Angerilli V, Pennelli G, Galuppini F, Realdon S, Fantin A, Savarino E, Farinati F, Mastracci L, Luchini C, Fassan M. Molecular subtyping of gastroesophageal dysplasia heterogeneity according to TCGA/ACRG classes. Virchows Arch 2022. [PMID: 35925389 DOI: 10.1007/s00428-022-03392-7] [Reference Citation Analysis]
85 Ritterhouse LL, Gogakos T. Molecular Biomarkers of Response to Cancer Immunotherapy. Clinics in Laboratory Medicine 2022. [DOI: 10.1016/j.cll.2022.05.004] [Reference Citation Analysis]
86 Martelli V, Pastorino A, Sobrero AF. Prognostic and predictive molecular biomarkers in advanced colorectal cancer. Pharmacol Ther 2022;236:108239. [PMID: 35780916 DOI: 10.1016/j.pharmthera.2022.108239] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Chen B, Yao Y, Mao D, Li C, Wang X, Sheng S, Zhang L, Wang X, Chen S, Xu W, Deng J, Sun C, Zhou Q, Lowe S, Bentley R, Shao W, Li H. A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma. Front Immunol 2022;13:928742. [DOI: 10.3389/fimmu.2022.928742] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Libera L, Sahnane N, Pepe F, Pisapia P, De Luca C, Russo G, Parente P, Covelli C, Chiaravalli AM, Sessa F, Malapelle U, Furlan D. Critical aspects of MSI testing in endometrial cancer: a comparison study. Hum Pathol 2022:S0046-8177(22)00187-3. [PMID: 35872156 DOI: 10.1016/j.humpath.2022.07.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Chiu PKF, Lee EKC, Chan MTY, Chan WHC, Cheung MH, Lam MHC, Ma ESK, Poon DMC. Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology. Front Oncol 2022;12:962958. [DOI: 10.3389/fonc.2022.962958] [Reference Citation Analysis]
90 Ramarao-Milne P, Kondrashova O, Patch AM, Nones K, Koufariotis LT, Newell F, Addala V, Lakis V, Holmes O, Leonard C, Wood S, Xu Q, Mukhopadhyay P, Naeini MM, Steinfort D, Williamson JP, Bint M, Pahoff C, Nguyen PT, Twaddell S, Arnold D, Grainge C, Basirzadeh F, Fielding D, Dalley AJ, Chittoory H, Simpson PT, Aoude LG, Bonazzi VF, Patel K, Barbour AP, Fennell DA, Robinson BW, Creaney J, Hollway G, Pearson JV, Waddell N. Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels. ESMO Open 2022;7:100540. [PMID: 35849877 DOI: 10.1016/j.esmoop.2022.100540] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
91 Xia L, Lin H, Zhou Y, Lian J. ZNF750 facilitates carcinogenesis via promoting the expression of long non-coding RNA CYTOR and influences pharmacotherapy response in colon adenocarcinoma. J Zhejiang Univ Sci B 2022;23:587-96. [PMID: 35794688 DOI: 10.1631/jzus.B2100939] [Reference Citation Analysis]
92 Huang Y, Liao J, Liang F, Lin P, Wu S, Ye Y, Gao M, Chen R, Zeng H, Yin X, Jiang Y, Ouyang N, Han P, Huang X. A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma. Int Immunopharmacol 2022;110:108846. [PMID: 35816946 DOI: 10.1016/j.intimp.2022.108846] [Reference Citation Analysis]
93 Tian Y, Bai F, Zhang D, Isaguliants M. HIF1α: A Novel Biomarker with Potential Prognostic and Immunotherapy in Pan-cancer. Oxidative Medicine and Cellular Longevity 2022;2022:1-17. [DOI: 10.1155/2022/1246267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Yan A, Chen Y, Bian R, Wang C, Que H, Shen Y, Lu X. The landscape of enhancer RNA identify prognosis-related molecular subtypes in gastric cancer. Cancer Med 2023;12:2046-57. [PMID: 35801342 DOI: 10.1002/cam4.4959] [Reference Citation Analysis]
95 Jiang W, Mei W, Xu S, Ling Y, Li W, Kuang J, Li H, Hui H, Li J, Cai M, Pan Z, Zhang H, Li L, Ding P. Clinical actionability of triaging DNA mismatch repair deficient colorectal cancer from biopsy samples using deep learning. eBioMedicine 2022;81:104120. [DOI: 10.1016/j.ebiom.2022.104120] [Reference Citation Analysis]
96 Marletta S, Fusco N, Munari E, Luchini C, Cimadamore A, Brunelli M, Querzoli G, Martini M, Vigliar E, Colombari R, Girolami I, Pagni F, Eccher A. Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. JPM 2022;12:1073. [DOI: 10.3390/jpm12071073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
97 Chen X, Yuan Y, Ren W, Zhou F, Huang X, Pu J, Niu X, Jiang X. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression. Front Oncol 2022;12:927988. [PMID: 35756681 DOI: 10.3389/fonc.2022.927988] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Ceccon C, Angerilli V, Rasola C, Procaccio L, Sabbadin M, Bergamo F, Malapelle U, Lonardi S, Fassan M. Microsatellite Instable Colorectal Adenocarcinoma Diagnostics: The Advent of Liquid Biopsy Approaches. Front Oncol 2022;12:930108. [DOI: 10.3389/fonc.2022.930108] [Reference Citation Analysis]
99 Shubin V, Shelygin Y, Achkasov S, Sushkov O, Nazarov I, Ponomarenko A, Alimova I, Loginova A, Tsukanov A. Microsatellite Instability in Russian Patients with Colorectal Cancer. IJMS 2022;23:7062. [DOI: 10.3390/ijms23137062] [Reference Citation Analysis]
100 Yamamoto K, Iwadate D, Kato H, Nakai Y, Tateishi K, Fujishiro M. Targeting autophagy as a therapeutic strategy against pancreatic cancer. J Gastroenterol 2022. [PMID: 35727403 DOI: 10.1007/s00535-022-01889-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
101 Xiang L, Lan C. Significance of a Tumor Mutation Burden Gene Signature with Prognosis and Immune Feature of Gastric Cancer Patients. Int J Genomics 2022;2022:7684606. [PMID: 35719415 DOI: 10.1155/2022/7684606] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
102 Adeleke S, Haslam A, Choy A, Diaz-Cano S, Galante JR, Mikropoulos C, Boussios S. Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls. Per Med 2022. [PMID: 35708161 DOI: 10.2217/pme-2021-0128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
103 Wang D, Xie B. Prognostic and tumor immunity implication of inflammatory bowel disease-associated genes in colorectal cancer. Eur J Med Res 2022;27:91. [PMID: 35698180 DOI: 10.1186/s40001-022-00720-0] [Reference Citation Analysis]
104 Wang C, Zhang L, Vakiani E, Shia J. Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both? Mod Pathol 2022. [PMID: 35668150 DOI: 10.1038/s41379-022-01109-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
105 Chen S, Su X, Mo Z. KCNN4 is a Potential Biomarker for Predicting Cancer Prognosis and an Essential Molecule that Remodels Various Components in the Tumor Microenvironment: A Pan-Cancer Study. Front Mol Biosci 2022;9:812815. [DOI: 10.3389/fmolb.2022.812815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Rios-Valencia J, Cruz-Reyes C, Galindo-García TA, Rosas-Camargo V, Gamboa-Domínguez A. Mismatch repair system in colorectal cancer. Frequency, cancer phenotype, and follow-up. Rev Gastroenterol Mex (Engl Ed) 2022:S2255-534X(22)00051-2. [PMID: 35661637 DOI: 10.1016/j.rgmxen.2022.05.017] [Reference Citation Analysis]
107 Orr C, Wang C, Firat C, Connell LC, Sheehan MR, Vakiani E, Stadler ZK, Shia J. Primary Clonal Loss of Mismatch Repair Protein on Immunohistochemistry: A Pattern of Abnormality That Warrants Genetic Workup. JCO Precis Oncol 2022;6:e2200111. [PMID: 35700411 DOI: 10.1200/PO.22.00111] [Reference Citation Analysis]
108 Okuno M, Mukai T, Iwata K, Watanabe N, Tanaka T, Iwasa T, Shimojo K, Ohashi Y, Takagi A, Ito Y, Tezuka R, Iwata S, Iwasa Y, Kochi T, Ogiso T, Hayashi H, Sugiyama A, Nishigaki Y, Tomita E. Evaluation of the Cell Block Method Using Overnight-Stored Bile for Malignant Biliary Stricture Diagnosis. Cancers (Basel) 2022;14:2701. [PMID: 35681681 DOI: 10.3390/cancers14112701] [Reference Citation Analysis]
109 Zhang J, Huang D, Saw PE, Song E. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol 2022:S1471-4906(22)00096-5. [PMID: 35624021 DOI: 10.1016/j.it.2022.04.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
110 Cherri S, Oneda E, Noventa S, Melocchi L, Zaniboni A. Microsatellite instability and chemosensitivity in solid tumours. Ther Adv Med Oncol 2022;14:175883592210993. [DOI: 10.1177/17588359221099347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Nocini R, Vianini M, Girolami I, Calabrese L, Scarpa A, Martini M, Morbini P, Marletta S, Brunelli M, Molteni G, Parwani A, Pantanowitz L, Eccher A. PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside. Clin Exp Dent Res 2022. [PMID: 35593124 DOI: 10.1002/cre2.590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
112 Ju HY, Ho JY, Kang J, Hur SY, Kim S, Choi YJ, Han MR. Whole-Exome Sequencing Reveals Clinical Potential of Circulating Tumor DNA from Peritoneal Fluid and Plasma in Endometrial Cancer. Cancers (Basel) 2022;14:2506. [PMID: 35626111 DOI: 10.3390/cancers14102506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Sankar K, Ye JC, Li Z, Zheng L, Song W, Hu-Lieskovan S. The role of biomarkers in personalized immunotherapy. Biomark Res 2022;10:32. [PMID: 35585623 DOI: 10.1186/s40364-022-00378-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
114 Risinskaya N, Mangasarova Y, Nikulina E, Kozhevnikova Y, Chabaeva J, Yushkova A, Magomedova A, Kulikov S, Julhakyan H, Kravchenko S, Sudarikov A. STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma. Current Oncology 2022;29:3449-59. [DOI: 10.3390/curroncol29050278] [Reference Citation Analysis]
115 Ying M, Pan J, Lu G, Zhou S, Fu J, Wang Q, Wang L, Hu B, Wei Y, Shen J. Development and validation of a radiomics-based nomogram for the preoperative prediction of microsatellite instability in colorectal cancer. BMC Cancer 2022;22:524. [PMID: 35534797 DOI: 10.1186/s12885-022-09584-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
116 André T, Cohen R, Salem ME. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. Am Soc Clin Oncol Educ Book 2022;42:1-9. [PMID: 35471834 DOI: 10.1200/EDBK_349557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
117 He J, Jiang Z, Lei J, Zhou W, Cui Y, Luo B, Zhang M. Prognostic Value and Therapeutic Perspectives of CXCR Members in the Glioma Microenvironment. Front Genet 2022;13:787141. [DOI: 10.3389/fgene.2022.787141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 He R, Man C, Huang J, He L, Wang X, Lang Y, Fan Y. Identification of RNA Methylation-Related lncRNAs Signature for Predicting Hot and Cold Tumors and Prognosis in Colon Cancer. Front Genet 2022;13:870945. [PMID: 35464855 DOI: 10.3389/fgene.2022.870945] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
119 Evrard C, Messina S, Sefrioui D, Frouin É, Auriault ML, Chautard R, Zaanan A, Jaffrelot M, De La Fouchardière C, Aparicio T, Coriat R, Godet J, Silvain C, Randrian V, Sabourin JC, Guimbaud R, Miquelestorena-Standley E, Lecomte T, Moulin V, Karayan-Tapon L, Tachon G, Tougeron D. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers. Int J Mol Sci 2022;23:4427. [PMID: 35457245 DOI: 10.3390/ijms23084427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
120 Higashigawa S, Matsubayashi H, Kiyozumi Y, Kado N, Nishimura S, Oishi T, Sugino T, Fushiki K, Shirasu H, Yasui H, Mamesaya N, Fukuzaki N, Kunitomo K, Horiuchi Y, Kenmotsu H, Serizawa M. Present status of germline findings in precision medicine for Japanese cancer patients: issues in the current system. Jpn J Clin Oncol 2022:hyac046. [PMID: 35411369 DOI: 10.1093/jjco/hyac046] [Reference Citation Analysis]
121 Zannoni GF, Bragantini E, Castiglione F, Fassan M, Troncone G, Inzani F, Pesci A, Santoro A, Fraggetta F. Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal from the Italian Study Group. Front Oncol 2022;12:805613. [DOI: 10.3389/fonc.2022.805613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Kang SY, Kim DG, Ahn S, Ha SY, Jang KT, Kim KM. Comparative analysis of microsatellite instability by next-generation sequencing, MSI PCR and MMR immunohistochemistry in 1942 solid cancers. Pathol Res Pract 2022;233:153874. [PMID: 35405622 DOI: 10.1016/j.prp.2022.153874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
123 Qiao PP, Tian KS, Han LT, Ma B, Shen CK, Zhao RY, Zhang Y, Wei WJ, Chen XP. Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma. Endocrine 2022. [PMID: 35366156 DOI: 10.1007/s12020-022-03031-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Zhang C, Chong X, Jiang F, Gao J, Chen Y, Jia K, Fan M, Liu X, An J, Li J, Zhang X, Shen L. Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer. J Extracell Vesicles 2022;11:e12209. [PMID: 35362262 DOI: 10.1002/jev2.12209] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
125 Rios-valencia J, Cruz-reyes C, Galindo-garcía T, Rosas-camargo V, Gamboa-domínguez A. Sistema de reparación de errores de emparejamiento en carcinoma colorrectal. Frecuencia, fenotipo y seguimiento. Revista de Gastroenterología de México 2022. [DOI: 10.1016/j.rgmx.2021.02.014] [Reference Citation Analysis]
126 Jiang A, Zhou Y, Gong W, Pan X, Gan X, Wu Z, Liu B, Qu L, Wang L, Georgieva M. CCNA2 as an Immunological Biomarker Encompassing Tumor Microenvironment and Therapeutic Response in Multiple Cancer Types. Oxidative Medicine and Cellular Longevity 2022;2022:1-35. [DOI: 10.1155/2022/5910575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
127 Chen R, Zhang H, Wu W, Li S, Wang Z, Dai Z, Liu Z, Zhang J, Luo P, Xia Z, Cheng Q. Antigen Presentation Machinery Signature-Derived CALR Mediates Migration, Polarization of Macrophages in Glioma and Predicts Immunotherapy Response. Front Immunol 2022;13:833792. [DOI: 10.3389/fimmu.2022.833792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Jing C, Wang J, Zhu M, Bai Z, Zhao B, Zhang J, Yin J, Yang X, Liu Z, Zhang Z, Deng W. Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. Cancer Immunol Immunother 2022. [PMID: 35304622 DOI: 10.1007/s00262-022-03174-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
129 Zhang X, Wu T, Cai X, Dong J, Xia C, Zhou Y, Ding R, Yang R, Tan J, Zhang L, Zhang Y, Wang Y, Dong C, Li Y. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities. Front Immunol 2022;13:795972. [DOI: 10.3389/fimmu.2022.795972] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
130 Bregni G, Beck B. Toward Targeted Therapies in Oesophageal Cancers: An Overview. Cancers (Basel) 2022;14:1522. [PMID: 35326673 DOI: 10.3390/cancers14061522] [Reference Citation Analysis]
131 Li P, Lai Y, Tian L, Zhou Q. The prognostic value of prognostic nutritional index in advanced cancer receiving PD-1/L1 inhibitors: A meta-analysis. Cancer Med 2022. [PMID: 35297197 DOI: 10.1002/cam4.4668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Berrino E, Filippi R, Visintin C, Peirone S, Fenocchio E, Farinea G, Veglio F, Aglietta M, Sapino A, Cereda M, Visintin R, Pasini B, Marchiò C. Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors. NPJ Precis Oncol 2022;6:15. [PMID: 35260767 DOI: 10.1038/s41698-022-00258-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
133 O'Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, Miller WH Jr, Safra T, Italiano A, Mileshkin L, Xu L, Jin F, Norwood K, Maio M. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. J Clin Oncol 2022;40:752-61. [PMID: 34990208 DOI: 10.1200/JCO.21.01874] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 31.0] [Reference Citation Analysis]
134 Monk BJ, Enomoto T, Martin Kast W, Mccormack M, S. P. Tan D, Wu X, González-martín A. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102385] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
135 Zhang Y, Du T, Chen X. ANXA2P2: A Potential Immunological and Prognostic Signature in Ovarian Serous Cystadenocarcinoma via Pan-Carcinoma Synthesis. Front Oncol 2022;12:818977. [PMID: 35211410 DOI: 10.3389/fonc.2022.818977] [Reference Citation Analysis]
136 Gong S, Wu C, Duan Y, Tang J, Wu P. A Comprehensive Pan-Cancer Analysis for Pituitary Tumor-Transforming Gene 1. Front Genet 2022;13:843579. [DOI: 10.3389/fgene.2022.843579] [Reference Citation Analysis]
137 Zhu M, Zhang L, Cui H, Zhao Q, Wang H, Zhai B, Jiang R, Jiang Z. Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy. Front Immunol 2021;12:800951. [PMID: 35069585 DOI: 10.3389/fimmu.2021.800951] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
138 Park JH, Kim EY, Luchini C, Eccher A, Tizaoui K, Shin JI, Lim BJ. Artificial Intelligence for Predicting Microsatellite Instability Based on Tumor Histomorphology: A Systematic Review. Int J Mol Sci 2022;23:2462. [PMID: 35269607 DOI: 10.3390/ijms23052462] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
139 Dong M, Shen W, Yang G, Yang Z, Li X. Analysis of m6A Methylation Modification Patterns and Tumor Immune Microenvironment in Breast Cancer. Front Cell Dev Biol 2022;10:785058. [PMID: 35178386 DOI: 10.3389/fcell.2022.785058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
140 Parente P, Malapelle U, Angerilli V, Balistreri M, Lonardi S, Pucciarelli S, De Luca C, Pepe F, Russo G, Vigliar E, Danza A, Scaramuzzi F, Troncone G, Graziano P, Fassan M. MMR profile and microsatellite instability status in colorectal mucinous adenocarcinoma with synchronous metastasis: a new clue for the clinical practice. J Clin Pathol 2022:jclinpath-2022-208143. [PMID: 35145019 DOI: 10.1136/jclinpath-2022-208143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
141 Gatius S, Velasco A, Varela M, Cuatrecasas M, Jares P, Setaffy L, Bonhomme B, Santon A, Lindemann K, Croce S, Davidson B, Lax S, Palacios J, Matias-guiu X. Comparison of the Idylla™ MSI assay with the Promega™ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study. Virchows Arch. [DOI: 10.1007/s00428-022-03291-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Fucà G, Cohen R, Lonardi S, Shitara K, Elez ME, Fakih M, Chao J, Klempner SJ, Emmett M, Jayachandran P, Bergamo F, García MD, Mazzoli G, Provenzano L, Colle R, Svrcek M, Ambrosini M, Randon G, Shah AT, Salati M, Fenocchio E, Salvatore L, Chida K, Kawazoe A, Conca V, Curigliano G, Corti F, Cremolini C, Overman M, Andre T, Pietrantonio F. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. J Immunother Cancer 2022;10:e004001. [DOI: 10.1136/jitc-2021-004001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
143 Gosmann D, Russelli L, Weber WA, Schwaiger M, Krackhardt AM, D'Alessandria C. Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy. EJNMMI Res 2022;12:5. [PMID: 35099641 DOI: 10.1186/s13550-022-00877-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
144 Pirš B, Škof E, Smrkolj V, Smrkolj Š. Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment. Cancers (Basel) 2022;14:631. [PMID: 35158899 DOI: 10.3390/cancers14030631] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
145 Samaison L, Uguen A. Idylla MSI test combined with immunohistochemistry is a valuable and cost effective strategy to search for microsatellite instable tumors of noncolorectal origin. Pathol Int 2022. [PMID: 35083825 DOI: 10.1111/pin.13208] [Reference Citation Analysis]
146 Han Q, Liu S, Cui Z, Wang Q, Ma T, Jiang L, Li X, Dai G. Case Report and Literature Review: Diagnosis, Tailored Genetic Counseling and Cancer Prevention for a Locally Advanced dMMR/MSI-H/TMB-H Lung Cancer Patient With Concurrent Lynch Syndrome Mediated by a Rare PMS2 Splicing Variant (c.1144+1G>A). Front Genet 2022;12:799807. [DOI: 10.3389/fgene.2021.799807] [Reference Citation Analysis]
147 Bellone M, Brevi A, Bronte V, Dusi S, Ferrucci PF, Nisticò P, Rosato A, Russo V, Sica A, Toietta G, Colombo MP. Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15-16, 2020. Cancer Immunol Immunother 2022. [PMID: 35034143 DOI: 10.1007/s00262-022-03145-0] [Reference Citation Analysis]
148 Zhang J, Yu S, Li Q, Wang Q, Zhang J. Increased co-expression of MEST and BRCA1 is associated with worse prognosis and immune infiltration in ovarian cancer. Gynecol Oncol 2022:S0090-8258(22)00018-X. [PMID: 35042621 DOI: 10.1016/j.ygyno.2022.01.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Fanale D, Corsini LR, Scalia R, Brando C, Cucinella A, Madonia G, Dimino A, Filorizzo C, Barraco N, Bono M, Fiorino A, Magrin L, Sciacchitano R, Perez A, Russo TDB, Pantuso G, Russo A, Bazan V. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors? Crit Rev Oncol Hematol 2022;:103597. [PMID: 35033663 DOI: 10.1016/j.critrevonc.2022.103597] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
150 Zhang F, Feng D, Wang X, Gu Y, Shen Z, Yang Y, Wang J, Zhong Q, Li D, Hu H, Han P. An Unfolded Protein Response Related Signature Could Robustly Predict Survival Outcomes and Closely Correlate With Response to Immunotherapy and Chemotherapy in Bladder Cancer. Front Mol Biosci 2021;8:780329. [PMID: 35004850 DOI: 10.3389/fmolb.2021.780329] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
151 Dwertmann Rico S, Büscheck F, Dum D, Luebke AM, Kluth M, Hube-Magg C, Hinsch A, Höflmayer D, Perez D, Izbicki JR, Neipp M, Mofid H, Daniels T, Isbert C, Fraune C, Möller K, Menz A, Bernreuther C, Lebok P, Clauditz T, Sauter G, Uhlig R, Wilczak W, Simon R, Steurer S, Burandt E, Marx A, Krech T. Mucin 5AC expression is common but unrelated to tumor progression in pancreatic adenocarcinoma. Int J Immunopathol Pharmacol 2022;36:3946320221106504. [PMID: 35764407 DOI: 10.1177/03946320221106504] [Reference Citation Analysis]
152 Kwapisz D. Cancer Immunotherapy Clinical Trials. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_205-2] [Reference Citation Analysis]
153 Bourhis A, Remoué A, Samaison L, Uguen A. Diagnostic mutationnel rapide Idylla™ : applications théranostiques actuelles et futures. Annales de Pathologie 2022. [DOI: 10.1016/j.annpat.2021.12.007] [Reference Citation Analysis]
154 Muñoz CC, Ares MS, López JRA. Colorectal carcinoma: From molecular pathology to clinical practice. Foundations of Colorectal Cancer 2022. [DOI: 10.1016/b978-0-323-90055-3.00008-9] [Reference Citation Analysis]
155 Veiga A, Queipo F, Bou G, Cepeda-emiliani A, Concha Á. Diagnostic, prognostic, predictive and therapeutic molecular biomarkers in CRC: Understanding the present and foreseeing the future. Foundations of Colorectal Cancer 2022. [DOI: 10.1016/b978-0-323-90055-3.00049-1] [Reference Citation Analysis]
156 马 成. Research Progress of MSI Gastric Cancer Subtypes. ACM 2022;12:6719-6723. [DOI: 10.12677/acm.2022.127969] [Reference Citation Analysis]
157 Kim M, Seo AN. Molecular Pathology of Gastric Cancer. J Gastric Cancer 2022;22:264. [DOI: 10.5230/jgc.2022.22.e35] [Reference Citation Analysis]
158 Reisenbüchler D, Wagner SJ, Boxberg M, Peng T. Local Attention Graph-Based Transformer for Multi-target Genetic Alteration Prediction. Lecture Notes in Computer Science 2022. [DOI: 10.1007/978-3-031-16434-7_37] [Reference Citation Analysis]
159 Aiyer KTS, Doeleman T, Ryan NA, Nielsen M, Crosbie EJ, Smit VTHBM, Morreau H, Goeman JJ, Bosse T. Validity of a two-antibody testing algorithm for mismatch repair deficiency testing in cancer; a systematic literature review and meta-analysis. Mod Pathol 2022;35:1775-83. [PMID: 36104536 DOI: 10.1038/s41379-022-01149-w] [Reference Citation Analysis]
160 Fankhauser R, Depatie N, Berryman R, Lucero OM, Kulkarni RP. Proteomic biomarker technology for cancer immunotherapy. Engineering Technologies and Clinical Translation 2022. [DOI: 10.1016/b978-0-323-90949-5.00007-3] [Reference Citation Analysis]
161 Mattiolo P, Kryklyva V, Brosens LA, Mafficini A, Lawlor RT, Milella M, Scarpa A, Corbo V, Luchini C. Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic. Expert Opinion on Therapeutic Targets. [DOI: 10.1080/14728222.2022.2021397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
162 Simbolo M, Bersani S, Vicentini C, Taormina SV, Ciaparrone C, Bagante F, Rusev B, Centonze G, Montresor M, Brunelli M, Pedron S, Mafficini A, Paolino G, Mattiolo P, Conci S, Milione M, Guglielmi A, Ruzzenente A, Scarpa A, Luchini C. Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumors display divergent genomic and transcriptomic profiles. Expert Opin Ther Targets 2021;:1-11. [PMID: 34873971 DOI: 10.1080/14728222.2021.2013801] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Li J, Xu Y, Peng G, Zhu K, Wu Z, Shi L, Wu G. Identification of the Nerve-Cancer Cross-Talk-Related Prognostic Gene Model in Head and Neck Squamous Cell Carcinoma. Front Oncol 2021;11:788671. [PMID: 34912722 DOI: 10.3389/fonc.2021.788671] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
164 Sorokin M, Rabushko E, Efimov V, Poddubskaya E, Sekacheva M, Simonov A, Nikitin D, Drobyshev A, Suntsova M, Buzdin A. Experimental and Meta-Analytic Validation of RNA Sequencing Signatures for Predicting Status of Microsatellite Instability. Front Mol Biosci 2021;8:737821. [PMID: 34888350 DOI: 10.3389/fmolb.2021.737821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
165 Peng YP, Wang R, Liu QD, Xu XW, Wei W, Huang XT, Peng XM, Liu ZG. Combination of Tumor Mutational Burden and Specific Gene Mutations Stratifies Outcome to Immunotherapy Across Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. Front Genet 2021;12:756506. [PMID: 34868231 DOI: 10.3389/fgene.2021.756506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
166 Panse J. Neue Therapien in der Onkologie – Wirkweise und Nebenwirkungen. Onkologie up2date 2021;3:289-307. [DOI: 10.1055/a-1510-3260] [Reference Citation Analysis]
167 Du F, Liu Y. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer. J Clin Lab Anal 2021;:e24141. [PMID: 34817097 DOI: 10.1002/jcla.24141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
168 Laktionov KK, Artamonova EV, Borisova TN, Breder VV, Bychkov IM, Vladimirova LI, Volkov NM, Ergnian SM, Zhabina AS, Kononets PV, Kuz’minov AE, Levchenko EV, Malikhova OA, Marinov DT, Miller SV, Moiseenko FV, Mochal’nikova VV, Novikov SN, Pikin OV, Reutova EV, Rodionov EO, Sakaeva DD, Semenova AI, Smolin AV, Sotnikov VM, Tuzikov SA, Turkin IN, Tiurin IE, Chkhikvadze VD, Kolbanov KI, Chernichenko AV, Fedenko AA, Filonenko EV, Nevol’skikh AA, Ivanov SA, Khailova ZV, Gevorkian TG, Butenko AV, Gil’mutdinova IR, Gridneva IV, Eremushkin MA, Zernova MA, Kasparov BS, Kovlen DV, Kondrat’eva KO, Konchugova TV, Korotkova SB, Krutov AA, Obukhova OA, Ponomarenko GN, Semiglazova TI, Stepanova AM, Tkachenko GA, Khulamkhanova MM. Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. J Mod Onco 2021;23:369-402. [DOI: 10.26442/18151434.2021.3.201048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
169 Bayle A, Basile D, Garinet S, Rance B, Laurent-Puig P, Blons H, Taieb J, Perkins G. Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers. Cancers (Basel) 2021;13:5750. [PMID: 34830904 DOI: 10.3390/cancers13225750] [Reference Citation Analysis]
170 Saevets VV, Shamanova AY, Rostovcev DM. Antitumor effect on immune control points (PD-1/PD-L1) in malignant neoplasms. jour 2021;20:78-84. [DOI: 10.52420/2071-5943-2021-20-4-78-84] [Reference Citation Analysis]
171 Ros J, Baraibar I, Martini G, Salvà F, Saoudi N, Cuadra-Urteaga JL, Dienstmann R, Tabernero J, Élez E. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Curr Treat Options Oncol 2021;22:113. [PMID: 34741675 DOI: 10.1007/s11864-021-00913-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
172 Lin Z, Cai M, Zhang P, Li G, Liu T, Li X, Cai K, Nie X, Wang J, Liu J, Liu H, Zhang W, Gao J, Wu C, Wang L, Fan J, Zhang L, Wang Z, Hou Z, Ma C, Yang K, Wu G, Tao K, Zhang T. Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer. J Immunother Cancer 2021;9:e003554. [PMID: 34725214 DOI: 10.1136/jitc-2021-003554] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
173 Lu Z, Chen H, Jiao X, Wang Y, Wu L, Sun H, Li S, Gong J, Li J, Zou J, Yang K, Hu Y, Mao B, Zhang L, Zhang X, Peng Z, Lu M, Wang Z, Zhang H, Shen L. Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer. Genome Med 2021;13:175. [PMID: 34732240 DOI: 10.1186/s13073-021-00997-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
174 Bigdeli A, Oran A, Sussman R. Tumor Mutational Burden Calculation and Microsatellite Instability Detection in Clinical Next-Generation Sequencing Assays. Advances in Molecular Pathology 2021;4:199-204. [DOI: 10.1016/j.yamp.2021.07.008] [Reference Citation Analysis]
175 Kanani A, Veen T, Søreide K. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. Br J Surg 2021:znab342. [PMID: 34694371 DOI: 10.1093/bjs/znab342] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
176 Shang S, Liu J, Verma V, Wu M, Welsh J, Yu J, Chen D. Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates. Cancer Commun (Lond) 2021;41:1086-99. [PMID: 34658186 DOI: 10.1002/cac2.12226] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
177 Smithgall MC, Remotti H, Hsiao SJ, Mansukhani M, Liu-Jarin X, Fernandes H. Investigation of discrepant mismatch repair immunohistochemistry and microsatellite instability polymerase chain reaction test results for gynecologic cancers using next-generation sequencing. Hum Pathol 2021;119:41-50. [PMID: 34666078 DOI: 10.1016/j.humpath.2021.10.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 da Cunha IW, de Almeida Coudry R, de Macedo MP, de Assis EACP, Stefani S, Soares FA. A call to action: molecular pathology in Brazil. Surg Exp Pathol 2021;4. [DOI: 10.1186/s42047-021-00096-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
179 Shimozaki K, Hayashi H, Tanishima S, Horie S, Chida A, Tsugaru K, Togasaki K, Kawasaki K, Aimono E, Hirata K, Nishihara H, Kanai T, Hamamoto Y. Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors. Sci Rep 2021;11:20003. [PMID: 34625576 DOI: 10.1038/s41598-021-99364-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
180 Wu W, Liu Y, Zeng S, Han Y, Shen H. Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes. J Hematol Oncol 2021;14:160. [PMID: 34620200 DOI: 10.1186/s13045-021-01166-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
181 Luchini C, Mafficini A, Chatterjee D, Piredda ML, Sciammarella C, Navale P, Malleo G, Mattiolo P, Marchegiani G, Pea A, Salvia R, Brosens LA, Paolino G, Mastrosimini MG, Silvestris N, Milella M, Cheng L, Adsay VN, Lawlor RT, Scarpa A. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites. Virchows Arch 2021. [PMID: 34613461 DOI: 10.1007/s00428-021-03205-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
182 Luchini C, Grant RC, Scarpa A, Gallinger S. Microsatellite instability/mismatch repair deficiency in pancreatic cancers: the same or different? Gut 2021;70:1809-11. [PMID: 33468535 DOI: 10.1136/gutjnl-2020-323805] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
183 Zhang A, Zhong G, Wang L, Cai R, Han R, Xu C, Chen S, Sun P, Chen H. Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma. Cancer Cell Int 2021;21:518. [PMID: 34583688 DOI: 10.1186/s12935-021-02217-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
184 Lawlor RT, Mafficini A, Sciammarella C, Cantù C, Rusev BC, Piredda ML, Antonello D, Grimaldi S, Bonizzato G, Sperandio N, Marchegiani G, Malleo G, Pea A, Salvia R, Mombello A, Mazzoleni G, Nottegar A, Hanspeter E, Riva G, Tomezzoli A, Bencivenga M, de Manzoni G, Pedron S, Paolino G, Mattiolo P, Brosens LA, Silvestris N, Fassan M, Cooke SL, Beer PA, Milella M, Adsay VN, Cheng L, Scarpa A, Luchini C. Genomic characterization of hepatoid tumors: context matters. Hum Pathol 2021;118:30-41. [PMID: 34562502 DOI: 10.1016/j.humpath.2021.09.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
185 Guo J, Wang Y, Chen J, Qiu W, Chen W. Systematic review and trial sequential analysis of high-intensity focused ultrasound combined with chemotherapy versus chemotherapy in the treatment of unresectable pancreatic ductal adenocarcinoma. Int J Hyperthermia 2021;38:1375-83. [PMID: 34541997 DOI: 10.1080/02656736.2021.1962550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
186 Jaffrelot M, Farés N, Brunac AC, Laurenty AP, Danjoux M, Grand D, Icher S, Meilleroux J, Mery E, Buscail E, Maulat C, Toulas C, Vande Perre P, Chipoulet E, Bonnet D, Staub A, Guimbaud R, Selves J. An unusual phenotype occurs in 15% of mismatch repair-deficient tumors and is associated with non-colorectal cancers and genetic syndromes. Mod Pathol 2021. [PMID: 34545179 DOI: 10.1038/s41379-021-00918-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
187 De Silva P, Bano S, Pogue BW, Wang KK, Maytin EV, Hasan T. Photodynamic priming with triple-receptor targeted nanoconjugates that trigger T cell-mediated immune responses in a 3D in vitro heterocellular model of pancreatic cancer. Nanophotonics 2021;10:3199-214. [DOI: 10.1515/nanoph-2021-0304] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
188 Yu F, Makrigiorgos A, Leong KW, Makrigiorgos GM. Sensitive detection of microsatellite instability in tissues and liquid biopsies: Recent developments and updates. Comput Struct Biotechnol J 2021;19:4931-40. [PMID: 34527197 DOI: 10.1016/j.csbj.2021.08.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
189 Weis LN, Tolaney SM, Barrios CH, Barroso-Sousa R. Tissue-agnostic drug approvals: how does this apply to patients with breast cancer? NPJ Breast Cancer 2021;7:120. [PMID: 34518552 DOI: 10.1038/s41523-021-00328-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
190 Ryan NAJ, Walker TDJ, Bolton J, Ter Haar N, Van Wezel T, Glaire MA, Church DN, Evans DG, Bosse T, Crosbie EJ. Histological and Somatic Mutational Profiles of Mismatch Repair Deficient Endometrial Tumours of Different Aetiologies. Cancers (Basel) 2021;13:4538. [PMID: 34572765 DOI: 10.3390/cancers13184538] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
191 Rochefort P, Desseigne F, Bonadona V, Dussart S, Coutzac C, Sarabi M, la Fouchardiere C. Immune checkpoint inhibitor sensitivity of DNA repair deficient tumors. Immunotherapy 2021;13:1205-13. [PMID: 34494466 DOI: 10.2217/imt-2021-0024] [Reference Citation Analysis]
192 Lu Z, Chen H, Jiao X, Zhou W, Han W, Li S, Liu C, Gong J, Li J, Zhang X, Wang X, Peng Z, Qi C, Wang Z, Li Y, Li J, Li Y, Brock M, Zhang H, Shen L. Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier. J Immunother Cancer 2020;8:e000631. [PMID: 32792359 DOI: 10.1136/jitc-2020-000631] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
193 Yang C, Xu C, Li X, Zhang Y, Zhang S, Zhang T, Zhang Y. Could Camrelizumab Plus Chemotherapy Improve Clinical Outcomes in Advanced Malignancy? A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:700165. [PMID: 34485135 DOI: 10.3389/fonc.2021.700165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
194 Rüschoff J, Baretton G, Bläker H, Dietmaier W, Dietel M, Hartmann A, Horn LC, Jöhrens K, Kirchner T, Knüchel R, Mayr D, Merkelbach-Bruse S, Schildhaus HU, Schirmacher P, Tiemann M, Tiemann K, Weichert W, Büttner R. MSI testing : What's new? What should be considered? Pathologe 2021;42:110-8. [PMID: 34477921 DOI: 10.1007/s00292-021-00948-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
195 Mazilu L, Suceveanu AI, Stanculeanu DL, Gheorghe AD, Fricatel G, Negru SM. Tumor microenvironment is not an 'innocent bystander' in the resistance to treatment of head and neck cancers (Review). Exp Ther Med 2021;22:1128. [PMID: 34466142 DOI: 10.3892/etm.2021.10562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
196 Marchetti A, Barbareschi M, Barberis M, Buglioni S, Buttitta F, Fassan M, Fontanini G, Marchiò C, Papotti M, Pruneri G, Scarpa A, Stanta G, Tallini G, Troncone G, Veronese SM, Truini M, Sapino A. Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network. Pathologica 2021;113:262-71. [PMID: 34463674 DOI: 10.32074/1591-951X-324] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
197 Ratovomanana T, Cohen R, Svrcek M, Renaud F, Cervera P, Siret A, Letourneur Q, Buhard O, Bourgoin P, Guillerm E, Dorard C, Nicolle R, Ayadi M, Touat M, Bielle F, Sanson M, Le Rouzic P, Buisine MP, Piessen G, Collura A, Fléjou JF, de Reyniès A, Coulet F, Ghiringhelli F, André T, Jonchère V, Duval A. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. Gastroenterology 2021;161:814-826.e7. [PMID: 33992635 DOI: 10.1053/j.gastro.2021.05.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
198 Thouvenin J, Martínez Chanzá N, Alhalabi O, Lang H, Tannir NM, Barthélémy P, Malouf GG. Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions. Cancers (Basel) 2021;13:4341. [PMID: 34503152 DOI: 10.3390/cancers13174341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
199 D'Alessio A, Cammarota A, Prete MG, Pressiani T, Rimassa L. The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. Curr Opin Oncol 2021;33:386-94. [PMID: 33867478 DOI: 10.1097/CCO.0000000000000744] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
200 Pietrantonio F, Lonardi S, Corti F, Infante G, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Curigliano G, Cremolini C, Ambrosini M, Ros J, Intini R, Nappo F, Damian S, Morano F, Fucà G, Overman M, Miceli R. Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer 2021;9:e003370. [PMID: 34429334 DOI: 10.1136/jitc-2021-003370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
201 Trojan J, Stintzing S, Haase O, Koch C, Ziegler P, Demes M, Jelas I. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer. Oncologist 2021. [PMID: 34431576 DOI: 10.1002/onco.13955] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
202 Luchini C, Grillo F, Fassan M, Vanoli A, Capelli P, Paolino G, Ingravallo G, Renzulli G, Doglioni C, D'Amuri A, Mattiolo P, Pecori S, Parente P, Florena AM, Zamboni G, Scarpa A. Malignant epithelial/exocrine tumors of the pancreas. Pathologica 2020;112:210-26. [PMID: 33179623 DOI: 10.32074/1591-951X-167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
203 Fassan M, Scarpa A, Remo A, De Maglio G, Troncone G, Marchetti A, Doglioni C, Ingravallo G, Perrone G, Parente P, Luchini C, Mastracci L. Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. Pathologica 2020;112:248-59. [PMID: 33179625 DOI: 10.32074/1591-951X-158] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
204 Błach J, Wojas-Krawczyk K, Nicoś M, Krawczyk P. Failure of Immunotherapy-The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer. Int J Mol Sci 2021;22:9030. [PMID: 34445735 DOI: 10.3390/ijms22169030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
205 Herbreteau G, Airaud F, Pierre-Noël E, Vallée A, Bézieau S, Théoleyre S, Blons H, Garinet S, Denis MG. MEM: An Algorithm for the Reliable Detection of Microsatellite Instability (MSI) on a Small NGS Panel in Colorectal Cancer. Cancers (Basel) 2021;13:4203. [PMID: 34439357 DOI: 10.3390/cancers13164203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
206 Li Z, Jia Y, Zhu H, Xing X, Pang F, Shan F, Li S, Wang D, Zhao F, Ma T, Wang S, Ji J. Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy. Gastric Cancer 2021;24:1342-54. [PMID: 34406546 DOI: 10.1007/s10120-021-01207-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
207 Pyo J, Park HJ. Treatment Efficacy of Immune Checkpoint Inhibitors for Patients with Advanced or Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:3599. [PMID: 34441895 DOI: 10.3390/jcm10163599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
208 Zhao S, Chen L, Zang Y, Liu W, Liu S, Teng F, Xue F, Wang Y. Endometrial cancer in Lynch syndrome. Int J Cancer 2021. [PMID: 34398969 DOI: 10.1002/ijc.33763] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
209 Choucair K, Radford M, Bansal A, Park R, Saeed A. Advances in immune therapies for the treatment of microsatellite instability‑high/deficient mismatch repair metastatic colorectal cancer (Review). Int J Oncol 2021;59:74. [PMID: 34396449 DOI: 10.3892/ijo.2021.5254] [Reference Citation Analysis]
210 Rumyantsev AA, Anokhin AY. The role of immunotherapy in the management of metastatic/recurrent female reproductive system neoplasms. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-9-76-86] [Reference Citation Analysis]
211 Russo A, Incorvaia L, Malapelle U, Del Re M, Capoluongo E, Vincenzi B, Chiari R, Cortesi L, Danesi R, Florena AM, Fontanini G, Gori S, Marchetti A, Normanno N, Pinto C, Sangiolo D, Silvestris N, Tagliaferri P, Tallini G, Cinieri S, Beretta G. The Tumor-Agnostic Treatment For Patients with Solid Tumors: a Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBIOC-SIF Italian Scientific Societies. Crit Rev Oncol Hematol 2021;:103436. [PMID: 34371157 DOI: 10.1016/j.critrevonc.2021.103436] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
212 Antoniotti C, Korn WM, Marmorino F, Rossini D, Lonardi S, Masi G, Randon G, Conca V, Boccaccino A, Tomasello G, Passardi A, Swensen J, Ugolini C, Oberley M, Tamburini E, Casagrande M, Domenyuk V, Fontanini G, Giordano M, Abraham J, Spetzler D, Falcone A, Lenz HJ, Cremolini C. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. Eur J Cancer 2021;155:73-84. [PMID: 34365081 DOI: 10.1016/j.ejca.2021.06.037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
213 Wijaya ST, Ngoi NY, Tan DS. The role of molecular tests for adjuvant and post-surgical treatment in gynaecological cancers. Best Pract Res Clin Obstet Gynaecol 2021:S1521-6934(21)00103-6. [PMID: 34456153 DOI: 10.1016/j.bpobgyn.2021.06.003] [Reference Citation Analysis]
214 Arrichiello G, Poliero L, Borrelli C, Paragliola F, Nacca V, Napolitano S, Corte CMD, Martini G, Martinelli E. Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? Cancer Treat Res Commun 2021;28:100442. [PMID: 34391139 DOI: 10.1016/j.ctarc.2021.100442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
215 Chang YC, Chan MH, Li CH, Fang CY, Hsiao M, Chen CL. Exosomal Components and Modulators in Colorectal Cancer: Novel Diagnosis and Prognosis Biomarkers. Biomedicines 2021;9:931. [PMID: 34440135 DOI: 10.3390/biomedicines9080931] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
216 Musaelyan AA, Nazarov VD, Budnikova AS, Lapin SV, Vorobyev SL, Emanuel VL, Zakharenko AA, Orlov SV. Clinical and morphological portrait of tumors with microsatellite instability. Usp mol onkol 2021;8:52-59. [DOI: 10.17650/2313-805x-2021-8-2-52-59] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
217 Auclin E, Vuagnat P, Smolenschi C, Taieb J, Adeva J, Nebot-Bral L, Garcia de Herreros M, Vidal Tocino R, Longo-Muñoz F, El Dakdouki Y, Martín-Romano P, Gaba L, Saurí T, Oliveres H, Castañón E, Garcia-Carbonero R, Besse B, Massard C, Mezquita L, Hollebecque A. Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors. Cancers (Basel) 2021;13:3776. [PMID: 34359675 DOI: 10.3390/cancers13153776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
218 Malapelle U, Parente P, Pepe F, De Luca C, Pisapia P, Sgariglia R, Nacchio M, Gragnano G, Russo G, Conticelli F, Bellevicine C, Vigliar E, Iaccarino A, Covelli C, Balistreri M, Clemente C, Perrone G, Danza A, Scaramuzzi F, Fassan M, Troncone G, Graziano P. Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting. Cells 2021;10:1878. [PMID: 34440647 DOI: 10.3390/cells10081878] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
219 Wu C, Duan Y, Gong S, Kallendrusch S, Schopow N, Osterhoff G. Integrative and Comprehensive Pancancer Analysis of Regulator of Chromatin Condensation 1 (RCC1). Int J Mol Sci 2021;22:7374. [PMID: 34298996 DOI: 10.3390/ijms22147374] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
220 Berrino E, Bragoni A, Annaratone L, Fenocchio E, Carnevale-Schianca F, Garetto L, Aglietta M, Sarotto I, Casorzo L, Venesio T, Sapino A, Marchiò C. Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients. Cancers (Basel) 2021;13:3376. [PMID: 34282766 DOI: 10.3390/cancers13133376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
221 Rizzo A, Ricci AD, Gadaleta-caldarola G. MSI-H/dMMR and cancer immunotherapy: current state and future implications. Expert Review of Precision Medicine and Drug Development 2021;6:345-7. [DOI: 10.1080/23808993.2021.1946391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
222 Qi R, Zhao Y, Guo Q, Mi X, Cheng M, Hou W, Zheng H, Hua B. Exosomes in the lung cancer microenvironment: biological functions and potential use as clinical biomarkers. Cancer Cell Int 2021;21:333. [PMID: 34193120 DOI: 10.1186/s12935-021-01990-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
223 Grassi E, Corbelli J, Papiani G, Barbera MA, Gazzaneo F, Tamberi S. Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer. Front Oncol 2021;11:601722. [PMID: 34249672 DOI: 10.3389/fonc.2021.601722] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
224 Lawlor RT, Mattiolo P, Mafficini A, Hong SM, Piredda ML, Taormina SV, Malleo G, Marchegiani G, Pea A, Salvia R, Kryklyva V, Shin JI, Brosens LA, Milella M, Scarpa A, Luchini C. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Cancers (Basel) 2021;13:3119. [PMID: 34206554 DOI: 10.3390/cancers13133119] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
225 Dedeurwaerdere F, Claes KB, Van Dorpe J, Rottiers I, Van der Meulen J, Breyne J, Swaerts K, Martens G. Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer. Sci Rep 2021;11:12880. [PMID: 34145315 DOI: 10.1038/s41598-021-91974-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
226 Cao W, Ma X, Fischer JV, Sun C, Kong B, Zhang Q. Immunotherapy in endometrial cancer: rationale, practice and perspectives. Biomark Res 2021;9:49. [PMID: 34134781 DOI: 10.1186/s40364-021-00301-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
227 Sagredou S, Dalezis P, Papadopoulou E, Voura M, Deligiorgi MV, Nikolaou M, Panayiotidis MI, Nasioulas G, Sarli V, Trafalis DT. Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden. Pharmaceutics 2021;13:885. [PMID: 34203761 DOI: 10.3390/pharmaceutics13060885] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
228 Wang H, Liu B, Wei J. Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy. Cancer Lett 2021;517:96-104. [PMID: 34129878 DOI: 10.1016/j.canlet.2021.06.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
229 Piredda ML, Ammendola S, Sciammarella C, Turri G, Bagante F, Fassan M, Mafficini A, Mombello A, Cataldi S, Paolino G, Mattiolo P, Florena AM, Genna M, Fior F, Cheng L, Lawlor RT, Scarpa A, Pedrazzani C, Luchini C. Colorectal cancer with microsatellite instability: Right-sided location and signet ring cell histology are associated with nodal metastases, and extranodal extension influences disease-free survival. Pathol Res Pract 2021;224:153519. [PMID: 34119815 DOI: 10.1016/j.prp.2021.153519] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
230 Wang Y, Tong Z, Zhang W, Zhang W, Buzdin A, Mu X, Yan Q, Zhao X, Chang HH, Duhon M, Zhou X, Zhao G, Chen H, Li X. FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients. Front Oncol 2021;11:683419. [PMID: 34164344 DOI: 10.3389/fonc.2021.683419] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
231 Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, Zeng WJ, Liu Z, Cheng Q. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res 2021;40:184. [PMID: 34088360 DOI: 10.1186/s13046-021-01987-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 39.5] [Reference Citation Analysis]
232 Vanmeerbeek I, Borras DM, Sprooten J, Bechter O, Tejpar S, Garg AD. Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy. Genes Immun 2021;22:108-19. [PMID: 34079092 DOI: 10.1038/s41435-021-00138-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
233 Xu J, Yang X, Mao Y, Mei J, Wang H, Ding J, Hua D. Removal of N-Linked Glycosylation Enhances PD-L1 Detection in Colon Cancer: Validation Research Based on Immunohistochemistry Analysis. Technol Cancer Res Treat 2021;20:15330338211019442. [PMID: 34060360 DOI: 10.1177/15330338211019442] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
234 Saeed OAM, Mann SA, Luchini C, Huang K, Zhang S, Sen JD, Piredda ML, Wang M, Baldrige LA, Sperling RM, Curless KL, Cheng L. Evaluating mismatch repair deficiency for solid tumor immunotherapy eligibility: immunohistochemistry versus microsatellite molecular testing. Hum Pathol 2021;115:10-8. [PMID: 34052294 DOI: 10.1016/j.humpath.2021.05.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
235 Rüschoff J, Baretton G, Bläker H, Dietmaier W, Dietel M, Hartmann A, Horn LC, Jöhrens K, Kirchner T, Knüchel R, Mayr D, Merkelbach-Bruse S, Schildhaus HU, Schirmacher P, Tiemann M, Tiemann K, Weichert W, Büttner R. [MSI testing : What is new? What should be considered? German version]. Pathologe 2021;42:414-23. [PMID: 34043067 DOI: 10.1007/s00292-021-00944-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
236 Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A, Germano G. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers (Basel) 2021;13:2638. [PMID: 34072037 DOI: 10.3390/cancers13112638] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
237 Sun J, Xu J, Sun C, Zheng M, Li Y, Zhu S, Zhang S. Screening and Prognostic Value of Methylated Septin9 and its Association With Clinicopathological and Molecular Characteristics in Colorectal Cancer. Front Mol Biosci 2021;8:568818. [PMID: 34095214 DOI: 10.3389/fmolb.2021.568818] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
238 Bateman AC. DNA mismatch repair protein immunohistochemistry - an illustrated guide. Histopathology 2021;79:128-38. [PMID: 33829541 DOI: 10.1111/his.14367] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
239 Sajjadi E, Venetis K, Piciotti R, Invernizzi M, Guerini-Rocco E, Haricharan S, Fusco N. Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization. Cancer Cell Int 2021;21:266. [PMID: 34001143 DOI: 10.1186/s12935-021-01976-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
240 Dong L, Zou S, Jin X, Lu H, Zhang Y, Guo L, Cai J, Ying J. Cytoplasmic MSH2 Related to Genomic Deletions in the MSH2/EPCAM Genes in Colorectal Cancer Patients With Suspected Lynch Syndrome. Front Oncol 2021;11:627460. [PMID: 34055602 DOI: 10.3389/fonc.2021.627460] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
241 Chen QY, Chen YX, Han QY, Zhang JG, Zhou WJ, Zhang X, Ye YH, Yan WH, Lin A. Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer. Front Immunol 2021;12:679090. [PMID: 34054869 DOI: 10.3389/fimmu.2021.679090] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
242 Zhang W, Yin H, Huang Z, Zhao J, Zheng H, He D, Li M, Tan W, Tian S, Song B. Development and validation of MRI-based deep learning models for prediction of microsatellite instability in rectal cancer. Cancer Med 2021;10:4164-73. [PMID: 33963688 DOI: 10.1002/cam4.3957] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
243 Shimada Y, Okuda S, Watanabe Y, Tajima Y, Nagahashi M, Ichikawa H, Nakano M, Sakata J, Takii Y, Kawasaki T, Homma KI, Kamori T, Oki E, Ling Y, Takeuchi S, Wakai T. Histopathological characteristics and artificial intelligence for predicting tumor mutational burden-high colorectal cancer. J Gastroenterol 2021;56:547-59. [PMID: 33909150 DOI: 10.1007/s00535-021-01789-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
244 Guyot D'Asnières De Salins A, Tachon G, Cohen R, Karayan-Tapon L, Junca A, Frouin E, Godet J, Evrard C, Randrian V, Duval A, Svrcek M, Lascols O, Vignot S, Coulet F, André T, Fléjou JF, Cervera P, Tougeron D. Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer. ESMO Open 2021;6:100120. [PMID: 33930657 DOI: 10.1016/j.esmoop.2021.100120] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
245 Corti F, Lonardi S, Intini R, Salati M, Fenocchio E, Belli C, Borelli B, Brambilla M, Prete AA, Quarà V, Antista M, Fassan M, Morano F, Spallanzani A, Ambrosini M, Curigliano G, de Braud F, Zagonel V, Fucà G, Pietrantonio F. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. Eur J Cancer 2021;150:155-67. [PMID: 33901794 DOI: 10.1016/j.ejca.2021.03.043] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
246 Salewski I, Kuntoff S, Kuemmel A, Feldtmann R, Felix SB, Henze L, Junghanss C, Maletzki C. Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors. Cancer Immunol Immunother 2021. [PMID: 33870463 DOI: 10.1007/s00262-021-02933-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
247 Tsukanov AS, Pikunov DY, Shubin VP, Barinov AA, Kashnikov VN, Shelygin YA, Kaprin AD, Filonenko EV, Sidorov DV, Maschan AA, Novichkova GA, Yasko LA, Raykina EV, Rumyantsev AG. Unique Combination of Diamond-Blackfan Anemia and Lynch Syndrome in Adult Female: A Case Report. Front Oncol 2021;11:652696. [PMID: 33937060 DOI: 10.3389/fonc.2021.652696] [Reference Citation Analysis]
248 Zhang N, Dai Z, Wu W, Wang Z, Cao H, Zhang Y, Wang Z, Zhang H, Cheng Q. The Predictive Value of Monocytes in Immune Microenvironment and Prognosis of Glioma Patients Based on Machine Learning. Front Immunol 2021;12:656541. [PMID: 33959130 DOI: 10.3389/fimmu.2021.656541] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 13.5] [Reference Citation Analysis]
249 Peña-Asensio J, Calvo H, Torralba M, Miquel J, Sanz-de-Villalobos E, Larrubia JR. Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1922. [PMID: 33923463 DOI: 10.3390/cancers13081922] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
250 Özdoğan M, Papadopoulou E, Tsoulos N, Tsantikidi A, Mariatou VM, Tsaousis G, Kapeni E, Bourkoula E, Fotiou D, Kapetsis G, Boukovinas I, Touroutoglou N, Fassas A, Adamidis A, Kosmidis P, Trafalis D, Galani E, Lypas G, Orhan B, Tansan S, Özatlı T, Kırca O, Çakır O, Nasioulas G. Comprehensive tumor molecular profile analysis in clinical practice. BMC Med Genomics 2021;14:105. [PMID: 33853586 DOI: 10.1186/s12920-021-00952-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
251 Lee CS, Song IH, Lee A, Kang J, Lee YS, Lee IK, Song YS, Lee SH. Enhancing the landscape of colorectal cancer using targeted deep sequencing. Sci Rep 2021;11:8154. [PMID: 33854094 DOI: 10.1038/s41598-021-87486-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
252 Fucà G, Corti F, Ambrosini M, Intini R, Salati M, Fenocchio E, Manca P, Manai C, Daniel F, Raimondi A, Morano F, Corallo S, Prisciandaro M, Spallanzani A, Quarà V, Belli C, Vaiani M, Curigliano G, Cremolini C, De Braud F, Di Bartolomeo M, Zagonel V, Lonardi S, Pietrantonio F. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer 2021;9:e002501. [PMID: 33849927 DOI: 10.1136/jitc-2021-002501] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
253 De Falco E, Pacini L, Bastianelli D, Spinelli GP, Spoto C, Veltri E, Calogero A. Concomitant Mutations G12D and G13D on the Exon 2 of the KRAS Gene: Two Cases of Women with Colon Adenocarcinoma. Diagnostics (Basel) 2021;11:659. [PMID: 33917572 DOI: 10.3390/diagnostics11040659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
254 Sychevskaya KA, Risinskaya NV, Kravchenko SK, Nikulina EE, Misyurina AE, Magomedova AU, Sudarikov AB. Pitfalls in mononucleotide microsatellite repeats instability assessing (MSI) in the patients with B-cell lymphomas. Klin Lab Diagn 2021;66:181-6. [PMID: 33793119 DOI: 10.51620/0869-2084-2021-66-3-181-186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
255 Wang JY, Xiu J, Baca Y, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Shields AF, Grothey A, Weinberg BA, Marshall JL, Lou E, Khushman M, Sohal DPS, Hall MJ, Oberley M, Spetzler D, Shen L, Korn WM, Lenz HJ. Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy. Ann Oncol 2021;32:906-16. [PMID: 33798656 DOI: 10.1016/j.annonc.2021.03.203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
256 Piciotti R, Venetis K, Sajjadi E, Fusco N. Mismatch Repair Status Characterization in Oncologic Pathology: Taking Stock of the Real-World Possibilities. JMP 2021;2:93-100. [DOI: 10.3390/jmp2020009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
257 Ghidini M, Petrillo A, Botticelli A, Trapani D, Parisi A, La Salvia A, Sajjadi E, Piciotti R, Fusco N, Khakoo S. How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches. J Clin Med 2021;10:1412. [PMID: 33915839 DOI: 10.3390/jcm10071412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
258 Wang Y, Wang S, Yang Q, Li J, Yu F, Zhao E. Norepinephrine Enhances Aerobic Glycolysis and May Act as a Predictive Factor for Immunotherapy in Gastric Cancer. J Immunol Res 2021;2021:5580672. [PMID: 33855088 DOI: 10.1155/2021/5580672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
259 Gilson P, Merlin JL, Harlé A. Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA). Cancers (Basel) 2021;13:1491. [PMID: 33804907 DOI: 10.3390/cancers13071491] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
260 Ukkola I, Nummela P, Pasanen A, Kero M, Lepistö A, Kytölä S, Bützow R, Ristimäki A. Detection of microsatellite instability with Idylla MSI assay in colorectal and endometrial cancer. Virchows Arch 2021. [PMID: 33755781 DOI: 10.1007/s00428-021-03082-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
261 Li ZZ, Liu PF, An TT, Yang HC, Zhang W, Wang JX. Construction of a prognostic immune signature for lower grade glioma that can be recognized by MRI radiomics features to predict survival in LGG patients. Transl Oncol 2021;14:101065. [PMID: 33761371 DOI: 10.1016/j.tranon.2021.101065] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
262 Seesaha PK, Wang KX, Wang GQ, Cui TY, Zhao FJ, Pan LL, Li XC, Shu YQ, Chen XF. Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer. Onco Targets Ther 2021;14:1873-82. [PMID: 33737812 DOI: 10.2147/OTT.S269671] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
263 Siemanowski J, Schömig-Markiefka B, Buhl T, Haak A, Siebolts U, Dietmaier W, Arens N, Pauly N, Ataseven B, Büttner R, Merkelbach-Bruse S. Managing Difficulties of Microsatellite Instability Testing in Endometrial Cancer-Limitations and Advantages of Four Different PCR-Based Approaches. Cancers (Basel) 2021;13:1268. [PMID: 33809329 DOI: 10.3390/cancers13061268] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
264 Xie C, Wu H, Pan T, Zheng X, Yang X, Zhang G, Lian Y, Lin J, Peng L. A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma. Aging (Albany NY) 2021;13:8563-87. [PMID: 33714200 DOI: 10.18632/aging.202670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
265 Vtorushin SV, Naumov SS, Stepanov IV, Sinyansky LE, Afanasyev SG. ROLE OF PD-L1 ASSESSMENT IN THE ASPECT OF MOLECULAR-GENETIC CLASSIFICATION OF COLORECTAL CANCER. CURRENT STATE OF THE PROBLEM. Sib onkol ž 2021;20:115-122. [DOI: 10.21294/1814-4861-2021-20-1-115-122] [Reference Citation Analysis]
266 Chen D, Wang Y, Zhang X, Ding Q, Wang X, Xue Y, Wang W, Mao Y, Chen C, Chen Y. Characterization of Tumor Microenvironment in Lung Adenocarcinoma Identifies Immune Signatures to Predict Clinical Outcomes and Therapeutic Responses. Front Oncol 2021;11:581030. [PMID: 33747907 DOI: 10.3389/fonc.2021.581030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
267 Ren XY, Song Y, Wang J, Chen LY, Pang JY, Zhou LR, Shen SJ, Cao X, Wang YX, Shao MM, Liang ZY, Sun Q, Wu HW. Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients. Front Oncol 2021;11:570623. [PMID: 33747906 DOI: 10.3389/fonc.2021.570623] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
268 Dum D, Steurer S, Simon R, Zimmermann PV, Burandt E, Clauditz TS, Fisch M, Rink M, Dahlem R, Höppner W, Zecha H, Doh O, Matthies C, Wilczak W, Sauter G, Fraune C. Mismatch repair deficiency occurs very rarely in seminomas. Transl Androl Urol 2021;10:1048-55. [PMID: 33850739 DOI: 10.21037/tau-20-1355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
269 Puliga E, Corso S, Pietrantonio F, Giordano S. Microsatellite instability in Gastric Cancer: Between lights and shadows. Cancer Treat Rev 2021;95:102175. [PMID: 33721595 DOI: 10.1016/j.ctrv.2021.102175] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 10.5] [Reference Citation Analysis]
270 Tokuyama N, Takegawa N, Nishikawa M, Sakai A, Mimura T, Kushida S, Tsumura H, Yamamoto Y, Miki I, Tsuda M. Pretreatment Glasgow prognostic score as a predictor of outcomes in nivolumab-treated patients with advanced gastric cancer. PLoS One 2021;16:e0247645. [PMID: 33635904 DOI: 10.1371/journal.pone.0247645] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
271 Dong X, Song J, Chen B, Qi Y, Jiang W, Li H, Zheng D, Wang Y, Zhang X, Liu H. Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma. Front Oncol 2020;10:592811. [PMID: 33718105 DOI: 10.3389/fonc.2020.592811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
272 Barresi V, Simbolo M, Fioravanzo A, Piredda ML, Caffo M, Ghimenton C, Pinna G, Longhi M, Nicolato A, Scarpa A. Molecular Profiling of 22 Primary Atypical Meningiomas Shows the Prognostic Significance of 18q Heterozygous Loss and CDKN2A/B Homozygous Deletion on Recurrence-Free Survival. Cancers (Basel) 2021;13:903. [PMID: 33670055 DOI: 10.3390/cancers13040903] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
273 Tarantino P, Mazzarella L, Marra A, Trapani D, Curigliano G. The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. Cancer Treat Rev 2021;94:102169. [PMID: 33652262 DOI: 10.1016/j.ctrv.2021.102169] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
274 Sobhani F, Robinson R, Hamidinekoo A, Roxanis I, Somaiah N, Yuan Y. Artificial intelligence and digital pathology: Opportunities and implications for immuno-oncology. Biochim Biophys Acta Rev Cancer 2021;1875:188520. [PMID: 33561505 DOI: 10.1016/j.bbcan.2021.188520] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
275 Lu X, Ji C, Jiang L, Zhu Y, Zhou Y, Meng J, Gao J, Lu T, Ye J, Yan F. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy. Cell Prolif 2021;54:e12979. [PMID: 33522069 DOI: 10.1111/cpr.12979] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
276 Santandrea G, Piana S, Valli R, Zanelli M, Gasparini E, De Leo A, Mandato VD, Palicelli A. Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature. Diagnostics (Basel) 2021;11:199. [PMID: 33572888 DOI: 10.3390/diagnostics11020199] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
277 Leclerc J, Vermaut C, Buisine MP. Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors. Cancers (Basel) 2021;13:467. [PMID: 33530449 DOI: 10.3390/cancers13030467] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
278 Li T, Li J. [Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer 
with Rare Mutation]. Zhongguo Fei Ai Za Zhi 2021;24:19-24. [PMID: 33478186 DOI: 10.3779/j.issn.1009-3419.2020.102.41] [Reference Citation Analysis]
279 Huang X, Liu J, Liu H, Mo X, Meng Y, Zhang L, Deng Y, Zhang Y, Tang W. A Combined Epithelial Mesenchymal Transformation and DNA Repair Gene Panel in Colorectal Cancer With Prognostic and Therapeutic Implication. Front Oncol 2020;10:595182. [PMID: 33520707 DOI: 10.3389/fonc.2020.595182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
280 Belli C, Penault-Llorca F, Ladanyi M, Normanno N, Scoazec JY, Lacroix L, Reis-Filho JS, Subbiah V, Gainor JF, Endris V, Repetto M, Drilon A, Scarpa A, André F, Douillard JY, Curigliano G. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol 2021;32:337-50. [PMID: 33455880 DOI: 10.1016/j.annonc.2020.11.021] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 16.5] [Reference Citation Analysis]
281 Dong A, Zhao Y, Li Z, Hu H. PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer? J Gene Med 2021;23:e3294. [PMID: 33171529 DOI: 10.1002/jgm.3294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
282 Lei Y, Zhang G, Zhang C, Xue L, Yang Z, Lu Z, Huang J, Zang R, Che Y, Mao S, Fang L, Liu C, Wang X, Zheng S, Sun N, He J. The average copy number variation (CNVA) of chromosome fragments is a potential surrogate for tumor mutational burden in predicting responses to immunotherapy in non-small-cell lung cancer. Clin Transl Immunology 2021;10:e1231. [PMID: 33425353 DOI: 10.1002/cti2.1231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
283 Ansari D, Andersson R. Biomarkers in Pancreatic Cancer. Textbook of Pancreatic Cancer 2021. [DOI: 10.1007/978-3-030-53786-9_31] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
284 Zhang W, Huang Z, Zhao J, He D, Li M, Yin H, Tian S, Zhang H, Song B. Development and validation of magnetic resonance imaging-based radiomics models for preoperative prediction of microsatellite instability in rectal cancer. Ann Transl Med 2021;9:134. [PMID: 33569436 DOI: 10.21037/atm-20-7673] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
285 Palle J, Taïeb J, Zaanan A. Biomarkers for Immunotherapy in Gastrointestinal Cancers. Cancer Immunotherapy 2021. [DOI: 10.1007/13905_2021_10] [Reference Citation Analysis]
286 Luchini C, Brosens LAA, Wood LD, Chatterjee D, Shin JI, Sciammarella C, Fiadone G, Malleo G, Salvia R, Kryklyva V, Piredda ML, Cheng L, Lawlor RT, Adsay V, Scarpa A. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut 2021;70:148-56. [PMID: 32350089 DOI: 10.1136/gutjnl-2020-320726] [Cited by in Crossref: 88] [Cited by in F6Publishing: 83] [Article Influence: 44.0] [Reference Citation Analysis]
287 Zhang Y, Lin A, Li Y, Ding W, Meng H, Luo P, Zhang J. Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer. Front Cell Dev Biol 2020;8:608969. [PMID: 33363171 DOI: 10.3389/fcell.2020.608969] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
288 Liu Y, Li N, Zhu X, Qi Y. How wide is the application of genetic big data in biomedicine. Biomed Pharmacother 2021;133:111074. [PMID: 33378973 DOI: 10.1016/j.biopha.2020.111074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
289 Hu H, Wu Z, Wang C, Huang Y, Zhang J, Cai Y, Xie X, Li J, Shen C, Li W, Ling J, Xu X, Deng Y. Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair. Front Oncol 2020;10:579478. [PMID: 33344234 DOI: 10.3389/fonc.2020.579478] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
290 Kato M, Sasaki T, Inoue T. Current experimental human tissue-derived models for prostate cancer research. Int J Urol 2021;28:150-62. [PMID: 33247498 DOI: 10.1111/iju.14441] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
291 Diao Z, Han Y, Chen Y, Zhang R, Li J. The clinical utility of microsatellite instability in colorectal cancer. Crit Rev Oncol Hematol 2021;157:103171. [PMID: 33290824 DOI: 10.1016/j.critrevonc.2020.103171] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
292 Jiang P, Li Y, Xu Z, He S. A signature of 17 immune-related gene pairs predicts prognosis and immune status in HNSCC patients. Transl Oncol 2021;14:100924. [PMID: 33221687 DOI: 10.1016/j.tranon.2020.100924] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
293 Adiga D, Eswaran S, Pandey D, Sharan K, Kabekkodu SP. Molecular landscape of recurrent cervical cancer. Crit Rev Oncol Hematol 2021;157:103178. [PMID: 33279812 DOI: 10.1016/j.critrevonc.2020.103178] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
294 Wu Y, Zhang L, He S, Guan B, He A, Yang K, Gong Y, Li X, Zhou L. Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer. Aging (Albany NY) 2020;12:23306-25. [PMID: 33221763 DOI: 10.18632/aging.104115] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 10.7] [Reference Citation Analysis]
295 Chapel DB, Ritterhouse LL. Microsatellite Instability Testing and Therapy Implications. Advances in Molecular Pathology 2020;3:169-188. [DOI: 10.1016/j.yamp.2020.07.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
296 Panse J. Neue Therapien in der Onkologie – Wirkweise und Nebenwirkungen. Zeitschrift für Palliativmedizin 2020;21:317-333. [DOI: 10.1055/a-1166-4330] [Reference Citation Analysis]
297 Jung G, Benítez-Ribas D, Sánchez A, Balaguer F. Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors-2020 Update. J Clin Med 2020;9:E3520. [PMID: 33142689 DOI: 10.3390/jcm9113520] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
298 Luchini C, Paolino G, Mattiolo P, Piredda ML, Cavaliere A, Gaule M, Melisi D, Salvia R, Malleo G, Shin JI, Cargnin S, Terrazzino S, Lawlor RT, Milella M, Scarpa A. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. J Exp Clin Cancer Res. 2020;39:227. [PMID: 33115526 DOI: 10.1186/s13046-020-01732-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
299 Cilona M, Locatello LG, Novelli L, Gallo O. The Mismatch Repair System (MMR) in Head and Neck Carcinogenesis and Its Role in Modulating the Response to Immunotherapy: A Critical Review. Cancers (Basel) 2020;12:E3006. [PMID: 33081243 DOI: 10.3390/cancers12103006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
300 Wang HC, Yeh TJ, Chan LP, Hsu CM, Cho SF. Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice. Int J Mol Sci 2020;21:E7621. [PMID: 33076306 DOI: 10.3390/ijms21207621] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
301 Lizardo DY, Kuang C, Hao S, Yu J, Huang Y, Zhang L. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Biochim Biophys Acta Rev Cancer 2020;1874:188447. [PMID: 33035640 DOI: 10.1016/j.bbcan.2020.188447] [Cited by in Crossref: 34] [Cited by in F6Publishing: 44] [Article Influence: 11.3] [Reference Citation Analysis]
302 Gilson P, Levy J, Rouyer M, Demange J, Husson M, Bonnet C, Salleron J, Leroux A, Merlin JL, Harlé A. Evaluation of 3 molecular-based assays for microsatellite instability detection in formalin-fixed tissues of patients with endometrial and colorectal cancers. Sci Rep 2020;10:16386. [PMID: 33009475 DOI: 10.1038/s41598-020-73421-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
303 Echle A, Grabsch HI, Quirke P, van den Brandt PA, West NP, Hutchins GGA, Heij LR, Tan X, Richman SD, Krause J, Alwers E, Jenniskens J, Offermans K, Gray R, Brenner H, Chang-Claude J, Trautwein C, Pearson AT, Boor P, Luedde T, Gaisa NT, Hoffmeister M, Kather JN. Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning. Gastroenterology 2020;159:1406-1416.e11. [PMID: 32562722 DOI: 10.1053/j.gastro.2020.06.021] [Cited by in Crossref: 125] [Cited by in F6Publishing: 122] [Article Influence: 41.7] [Reference Citation Analysis]
304 Wen DG, Zhao XP, You Y, Liu ZJ. Systematic analysis of immune-related genes based on a combination of multiple databases to build a diagnostic and a prognostic risk model for hepatocellular carcinoma. Cancer Immunol Immunother 2021;70:773-86. [PMID: 32989553 DOI: 10.1007/s00262-020-02733-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
305 Singh N, Wong R, Tchrakian N, Allen SG, Clarke B, Gilks CB. Interpretation of mismatch repair protein expression using obsolete criteria results in discrepancies with microsatellite instability and mutational testing results. Comment on Hechtman et al. Mod Pathol 2020; 33:871-879. Mod Pathol 2021;34:1031-2. [PMID: 32980858 DOI: 10.1038/s41379-020-00680-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
306 Cao R, Yang F, Ma SC, Liu L, Zhao Y, Li Y, Wu DH, Wang T, Lu WJ, Cai WJ, Zhu HB, Guo XJ, Lu YW, Kuang JJ, Huan WJ, Tang WM, Huang K, Huang J, Yao J, Dong ZY. Development and interpretation of a pathomics-based model for the prediction of microsatellite instability in Colorectal Cancer. Theranostics 2020;10:11080-91. [PMID: 33042271 DOI: 10.7150/thno.49864] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 16.0] [Reference Citation Analysis]
307 Malapelle U, Parente P, Pepe F, De Luca C, Cerino P, Covelli C, Balestrieri M, Russo G, Bonfitto A, Pisapia P, Fiordelisi F, D'Armiento M, Bruzzese D, Loupakis F, Pietrantonio F, Triassi M, Fassan M, Troncone G, Graziano P. Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. Cells 2020;9:E2019. [PMID: 32887373 DOI: 10.3390/cells9092019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
308 Wimmer K, Hulla W, Zschocke J, Lax SF, Webersinke G, Zelger B, Uyanik G, Kain R, Speicher M, Hoefler G. Erfassung von erblichem Dickdarm- und Gebärmutterkrebs. Onkologe 2020;26:846-855. [DOI: 10.1007/s00761-020-00773-y] [Reference Citation Analysis]
309 Lombardi G, Barresi V, Indraccolo S, Simbolo M, Fassan M, Mandruzzato S, Simonelli M, Caccese M, Pizzi M, Fassina A, Padovan M, Masetto E, Gardiman MP, Bonavina MG, Caffo M, Persico P, Chioffi F, Denaro L, Dei Tos AP, Scarpa A, Zagonel V. Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. Cancers (Basel) 2020;12:E2283. [PMID: 32823925 DOI: 10.3390/cancers12082283] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 9.7] [Reference Citation Analysis]
310 Kryklyva V, Ter Linden E, Kroeze LI, de Voer RM, van der Kolk BM, Stommel MWJ, Hermans JJ, Luchini C, Wood LD, Hruban RH, Nagtegaal ID, Ligtenberg MJL, Brosens LAA. Medullary Pancreatic Carcinoma Due to Somatic POLE Mutation: A Distinctive Pancreatic Carcinoma With Marked Long-Term Survival. Pancreas 2020;49:999-1003. [PMID: 32658072 DOI: 10.1097/MPA.0000000000001588] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
311 Rumyantsev AА. Molecular-guided therapy for disseminated cervical cancer: present and future. Medicinskij sovet 2020. [DOI: 10.21518/2079-701x-2020-9-121-126] [Reference Citation Analysis]
312 Rau TT, Bettschen E, Büchi C, Christe L, Rohner A, Müller MD, Carlson JW, Imboden S, Zlobec I. Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups. Mod Pathol 2021;34:222-32. [PMID: 32728223 DOI: 10.1038/s41379-020-0626-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
313 Cai L, Sun Y, Wang K, Guan W, Yue J, Li J, Wang R, Wang L. The Better Survival of MSI Subtype Is Associated With the Oxidative Stress Related Pathways in Gastric Cancer. Front Oncol 2020;10:1269. [PMID: 32850385 DOI: 10.3389/fonc.2020.01269] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
314 Leskela S, Romero I, Cristobal E, Pérez-Mies B, Rosa-Rosa JM, Gutierrez-Pecharroman A, Caniego-Casas T, Santón A, Ojeda B, López-Reig R, Palacios-Berraquero ML, García Á, Ibarra J, Hakim S, Guarch R, López-Guerrero JA, Poveda A, Palacios J. Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences. Am J Surg Pathol 2020;44:649-56. [PMID: 32294063 DOI: 10.1097/PAS.0000000000001432] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
315 Cohen R, Shi Q, André T. Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future. Cancers (Basel) 2020;12:E1990. [PMID: 32708216 DOI: 10.3390/cancers12071990] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
316 Obayashi M, Shibasaki Y, Koakutsu T, Hayashi Y, Shoji T, Hirayama K, Yamazaki M, Takayanagi Y, Shibata H, Nakamura M, Maruo H. Pancreatic undifferentiated carcinoma with osteoclast-like giant cells curatively resected after pembrolizumab therapy for lung metastases: a case report. BMC Gastroenterol 2020;20:220. [PMID: 32652936 DOI: 10.1186/s12876-020-01362-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
317 Yoshino T, Pentheroudakis G, Mishima S, Overman M, Yeh K, Baba E, Naito Y, Calvo F, Saxena A, Chen L, Takeda M, Cervantes A, Taniguchi H, Yoshida K, Kodera Y, Kitagawa Y, Tabernero J, Burris H, Douillard J. JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Annals of Oncology 2020;31:861-72. [DOI: 10.1016/j.annonc.2020.03.299] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 16.3] [Reference Citation Analysis]
318 Baraibar I, Ros J, Mulet N, Salvà F, Argilés G, Martini G, Cuadra JL, Sardo E, Ciardiello D, Tabernero J, Élez E. Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update. Expert Rev Mol Diagn 2020;20:653-64. [PMID: 32552041 DOI: 10.1080/14737159.2020.1782194] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
319 Horimoto Y, Thinzar Hlaing M, Saeki H, Kitano S, Nakai K, Sasaki R, Kurisaki-Arakawa A, Arakawa A, Otsuji N, Matsuoka S, Tokuda E, Arai M, Saito M. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer. Cancer Sci 2020;111:2647-54. [PMID: 32449246 DOI: 10.1111/cas.14500] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
320 Penas-Prado M, Armstrong TS, Gilbert MR. Progress in rare central nervous system tumors. Curr Opin Neurol 2019;32:895-906. [PMID: 31577601 DOI: 10.1097/WCO.0000000000000755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
321 Pécriaux A, Favre L, Calderaro J, Charpy C, Derman J, Pujals A. Detection of microsatellite instability in a panel of solid tumours with the Idylla MSI Test using extracted DNA. J Clin Pathol 2021;74:36-42. [PMID: 32513848 DOI: 10.1136/jclinpath-2020-206581] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
322 Riechelmann RP, Peixoto RD, Fernandes GDS, Weschenfelder RF, Prolla G, Filho DR, Andrade AC, Crosara M, Rego JFM, Gansl RC, Coimbra F, Aguiar S Jr, Carvalho E, Hoff PM, Coutinho AK. Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group. Ecancermedicalscience 2020;14:1048. [PMID: 32565901 DOI: 10.3332/ecancer.2020.1048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
323 Post CCB, Westermann AM, Bosse T, Creutzberg CL, Kroep JR. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. Crit Rev Oncol Hematol 2020;152:102973. [PMID: 32497971 DOI: 10.1016/j.critrevonc.2020.102973] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
324 Teixido C, Reguart N. Using biomarkers to determine optimal combinations with immunotherapy (biomarker discovery perspective). Future Oncol 2020;16:1677-81. [PMID: 32407147 DOI: 10.2217/fon-2020-0171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
325 Tuo Z, Zheng X, Zong Y, Li J, Zou C, Lv Y, Liu J. HK3 is correlated with immune infiltrates and predicts response to immunotherapy in non-small cell lung cancer. Clin Transl Med 2020;10:319-30. [PMID: 32508023 DOI: 10.1002/ctm2.6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
326 Tryakin AA, Fedyanin MY, Tsukanov AS, Shelygin YA, Pokataev IA, Ignatova EO, Khakimova GG, Frolova MA, Tjulandin SA. Microsatellite instability as a unique characteristic of tumors and a predictor of response to immune therapy. Malignant Tumours 2020;9:59-69. [DOI: 10.18027/2224-5057-2019-9-4-59-69] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
327 Steeghs EMP, Kroeze LI, Tops BBJ, van Kempen LC, Ter Elst A, Kastner-van Raaij AWM, Hendriks-Cornelissen SJB, Hermsen MJW, Jansen EAM, Nederlof PM, Schuuring E, Ligtenberg MJL, Eijkelenboom A. Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material. BMC Cancer 2020;20:291. [PMID: 32264863 DOI: 10.1186/s12885-020-06785-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
328 Huang Z, Zhang W, He D, Cui X, Tian S, Yin H, Song B. Development and validation of a radiomics model based on T2WI images for preoperative prediction of microsatellite instability status in rectal cancer: Study Protocol Clinical Trial (SPIRIT Compliant). Medicine (Baltimore) 2020;99:e19428. [PMID: 32150094 DOI: 10.1097/MD.0000000000019428] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
329 Schneeweiss A, Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Belleville E, Huober J, Thill M, Fasching PA, Kolberg HC, Pöschke P, Welslau M, Overkamp F, Tesch H, Fehm TN, Lüftner D, Schütz F. Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies. Geburtshilfe Frauenheilkd 2020;80:277-87. [PMID: 32139917 DOI: 10.1055/a-1111-2431] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
330 Cao R, Yang F, Ma S, Liu L, Li Y, Wu D, Zhao Y, Wang T, Lu W, Cai W, Zhu H, Guo X, Lu Y, Kuang J, Huan W, Tang W, Huang J, Yao J, Dong Z. A transferrable and interpretable multiple instance learning model for microsatellite instability prediction based on histopathology images.. [DOI: 10.1101/2020.02.29.971150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
331 Jiao Q, Ren Y, Ariston Gabrie AN, Wang Q, Wang Y, Du L, Liu X, Wang C, Wang Y. Advances of immune checkpoints in colorectal cancer treatment. Biomedicine & Pharmacotherapy 2020;123:109745. [DOI: 10.1016/j.biopha.2019.109745] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
332 Rachiglio AM, Sacco A, Forgione L, Esposito C, Chicchinelli N, Normanno N. Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. Exploration of Targeted Anti-tumor Therapy 2020;1:53-70. [DOI: 10.37349/etat.2020.00004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
333 Jia M, Yao L, Yang Q, Chi T. Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma. Front Oncol 2020;10:168. [PMID: 32154170 DOI: 10.3389/fonc.2020.00168] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
334 Zhang Y, Wang L, Li R, Liu B. The emerging development of tumor mutational burden in patients with NSCLC. Future Oncol 2020;16:469-81. [PMID: 32048882 DOI: 10.2217/fon-2019-0650] [Reference Citation Analysis]
335 Cohen R, Pudlarz T, Garcia-Larnicol ML, Vernerey D, Dray X, Clavel L, Jary M, Piessen G, Zaanan A, Aparicio T, Louvet C, Tournigand C, Chibaudel B, Tougeron D, Guimbaud R, Benouna J, Adenis A, Sokol H, Borg C, Duval A, Svrcek M, André T. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]. Bull Cancer 2020;107:438-46. [PMID: 32057467 DOI: 10.1016/j.bulcan.2019.11.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
336 Gazouli I, Zarkavelis G, Mauri D, Pentheroudakis G. Mismatch repair deficiency/microsatellite instability testing as predictive immunotherapy biomarkers-possible diagnostic missteps trusting a single method. Ann Transl Med 2019;7:S329. [PMID: 32016047 DOI: 10.21037/atm.2019.09.144] [Reference Citation Analysis]
337 Michaelidou K, Agelaki S, Mavridis K. Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises. Expert Rev Mol Diagn 2020;20:335-44. [PMID: 32000550 DOI: 10.1080/14737159.2020.1724785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
338 Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol 2020;72:307-19. [PMID: 31954494 DOI: 10.1016/j.jhep.2019.09.025] [Cited by in Crossref: 183] [Cited by in F6Publishing: 183] [Article Influence: 61.0] [Reference Citation Analysis]
339 Fanelli GN, Dal Pozzo CA, Depetris I, Schirripa M, Brignola S, Biason P, Balistreri M, Dal Santo L, Lonardi S, Munari G, Loupakis F, Fassan M. The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. Cancer Cell Int. 2020;20:30. [PMID: 32015690 DOI: 10.1186/s12935-020-1117-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
340 Bazzichetto C, Conciatori F, Luchini C, Simionato F, Santoro R, Vaccaro V, Corbo V, Falcone I, Ferretti G, Cognetti F, Melisi D, Scarpa A, Ciuffreda L, Milella M. From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. Cells 2020;9:E309. [PMID: 32012917 DOI: 10.3390/cells9020309] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
341 Cedrés S, Ponce-Aix S, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Gómez-Abecia S, Zucchiatti AC, Sansano I, Enguita AB, Miquel JM, Viaplana C, Dienstmann R, Paz-Ares L, Felip E. Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. Clin Transl Oncol 2020;22:1390-8. [PMID: 31916017 DOI: 10.1007/s12094-019-02275-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
342 Kurata K, Kubo M, Kai M, Mori H, Kawaji H, Kaneshiro K, Yamada M, Nishimura R, Osako T, Arima N, Okido M, Oda Y, Nakamura M. Microsatellite instability in Japanese female patients with triple-negative breast cancer. Breast Cancer 2020;27:490-8. [PMID: 31907878 DOI: 10.1007/s12282-019-01043-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
343 Bubendorf L, Firat P, Kulac I, Pisapia P, Savic-prince S, Santos G, Troncone G. Ancillary Studies for Serous Fluids. The International System for Serous Fluid Cytopathology 2020. [DOI: 10.1007/978-3-030-53908-5_8] [Reference Citation Analysis]
344 El Bairi K, Afqir S. Next-Generation Sequencing for Colorectal Cancer Management. Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing 2020. [DOI: 10.1007/978-3-030-53821-7_4] [Reference Citation Analysis]
345 Kang J, Jeong JH, Hwang HS, Lee SS, Park DH, Oh DW, Song TJ, Kim KH, Hwang S, Hwang DW, Kim SC, Park JH, Hong SM, Kim KP, Ryoo BY, Yoo C. Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response. Cancer Res Treat 2020;52:594-603. [PMID: 32019287 DOI: 10.4143/crt.2019.493] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 8.5] [Reference Citation Analysis]
346 Mann SA, Cheng L. Microsatellite instability and mismatch repair deficiency in the era of precision immuno-oncology. Expert Rev Anticancer Ther 2020;20:1-4. [PMID: 31842633 DOI: 10.1080/14737140.2020.1705789] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
347 Banias L, Jung I, Bara T, Fulop Z, Simu P, Simu I, Satala C, Gurzu S. Immunohistochemical-based molecular subtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymal transition. Oncol Lett. 2020;19:1487-1495. [PMID: 31966075 DOI: 10.3892/ol.2019.11228] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
348 Fatehi Hassanabad A, Chehade R, Breadner D, Raphael J. Esophageal carcinoma: Towards targeted therapies. Cell Oncol (Dordr) 2020;43:195-209. [PMID: 31848929 DOI: 10.1007/s13402-019-00488-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 62] [Article Influence: 13.5] [Reference Citation Analysis]
349 Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Belleville E, Schütz F, Fasching PA, Kolberg HC, Welslau M, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Lüftner D. Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. Geburtshilfe Frauenheilkd 2019;79:1309-19. [PMID: 31875860 DOI: 10.1055/a-1039-4458] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
350 Svrcek M. Vers un screening systématique du statut MMR déficient/MSI sur toutes les biopsies de cancers de l’estomac. Annales de Pathologie 2019;39:381-2. [DOI: 10.1016/j.annpat.2019.10.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
351 Andersson R, Pereira C, Bauden M, Ansari D. Is immunotherapy the holy grail for pancreatic cancer? Immunotherapy 2019;11:1435-8. [DOI: 10.2217/imt-2019-0164] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
352 Paulsson JO, Backman S, Wang N, Stenman A, Crona J, Thutkawkorapin J, Ghaderi M, Tham E, Stålberg P, Zedenius J, Juhlin CC. Whole-genome sequencing of synchronous thyroid carcinomas identifies aberrant DNA repair in thyroid cancer dedifferentiation. J Pathol 2020;250:183-94. [PMID: 31621921 DOI: 10.1002/path.5359] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
353 Huyghe N, Baldin P, Van den Eynde M. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? Gastroenterol Rep (Oxf) 2020;8:11-24. [PMID: 32104582 DOI: 10.1093/gastro/goz061] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 11.5] [Reference Citation Analysis]
354 Kim JY, Kronbichler A, Eisenhut M, Hong SH, van der Vliet HJ, Kang J, Shin JI, Gamerith G. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E1798. [PMID: 31731749 DOI: 10.3390/cancers11111798] [Cited by in Crossref: 59] [Cited by in F6Publishing: 68] [Article Influence: 14.8] [Reference Citation Analysis]
355 Fassan M, Brignola S, Pennelli G, Alberti G, Angerilli V, Bressan A, Pellino A, Lanza C, Salmaso R, Lonardi S, Pucciarelli S, Spolverato G, Scarpa M, Realdon S, Farinati F, Luchini C, Rugge M, Loupakis F. PD-L1 expression in gastroesophageal dysplastic lesions. Virchows Arch 2020;477:151-6. [DOI: 10.1007/s00428-019-02693-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
356 Bartha Á, Győrffy B. Comprehensive Outline of Whole Exome Sequencing Data Analysis Tools Available in Clinical Oncology. Cancers (Basel) 2019;11:E1725. [PMID: 31690036 DOI: 10.3390/cancers11111725] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
357 Silva VSE, De Brot L, Riechelmann RP. Testing microsatellite instability in solid tumors: the ideal versus what is real. Ann Transl Med 2019;7:600. [PMID: 32047761 DOI: 10.21037/atm.2019.09.124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
358 Lee MKC, Loree JM. Current and emerging biomarkers in metastatic colorectal cancer. Curr Oncol 2019;26:S7-S15. [PMID: 31819705 DOI: 10.3747/co.26.5719] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
359 Kloor M. Resistance of the stable-towards more precise prediction of response to immune checkpoint blockade in microsatellite-unstable cancer patients. Ann Transl Med 2019;7:603. [PMID: 32047764 DOI: 10.21037/atm.2019.10.29] [Reference Citation Analysis]
360 Kim JY, Lee KH, Kang J, Borcoman E, Saada-Bouzid E, Kronbichler A, Hong SH, de Rezende LFM, Ogino S, Keum N, Song M, Luchini C, van der Vliet HJ, Shin JI, Gamerith G. Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;11. [PMID: 31683809 DOI: 10.3390/cancers11111699] [Cited by in Crossref: 51] [Cited by in F6Publishing: 57] [Article Influence: 12.8] [Reference Citation Analysis]
361 Röcken C. Molekularpathologie zur Prädiktion von Prognose und Therapie bei Tumorerkrankungen. Onkologe 2019;25:54-60. [DOI: 10.1007/s00761-019-0640-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
362 Barresi V, Simbolo M, Mafficini A, Piredda ML, Caffo M, Cardali SM, Germanò A, Cingarlini S, Ghimenton C, Scarpa A. Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment. Cancers (Basel) 2019;11:E1279. [PMID: 31480372 DOI: 10.3390/cancers11091279] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
363 Mishima S, Taniguchi H, Akagi K, Baba E, Fujiwara Y, Hirasawa A, Ikeda M, Maeda O, Muro K, Nishihara H, Nishiyama H, Takano T, Tsuchihara K, Yatabe Y, Kodera Y, Yoshino T. Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition. Int J Clin Oncol 2020;25:217-39. [PMID: 31286289 DOI: 10.1007/s10147-019-01498-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
364 Andabekov TT, Rodina MK, Raskin GA, Cham KG, Rutkin IO. Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report. Opuholi ženskoj reproduktivnoj sistemy 2019;15:73-77. [DOI: 10.17650/1994-4098-2019-15-1-73-77] [Reference Citation Analysis]